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1. ABSTRACT 
 
Radiotherapy (RT) is one of the most effective non-surgical treatments of cancer patients 
with better functional preservation and less systemic influences. Resistance of tumor cells to RT is 
one of the most important causes of treatment failure, and the mechanism behind this process 
remains to be investigated in details. Cellular response to γ-rays is mediated by Ataxia 
telangiectasia mutated (ATM) kinase and the downstream effector p53. When p53 is 
phosphorylated, it can transactivate several genes to induce permanent cell cycle arrest (senescence) 
or apoptosis. Epithelial and mesenchymal cells as well as their derived tumor cells are more 
resistant to radiation-induced apoptosis and respond mainly by activating senescence. Hence, tumor 
cells in a senescent state might remain as “dormant” malignant cell and therefore represent a 
dangerous potential for tumor relapses. Through disruption of p53 function, cells may overcome 
growth arrest. A particular type of relapses after γ-rays was observed in patients with colorectal 
cancer, where oncocytic features were acquired in the recurring neoplasia after radiation therapy. 
Oncocytic tumors are characterized by aberrant biogenesis of nonfunctional mitochondria in their 
cells. They are mainly non-aggressive neoplasms and their low proliferation degree can be 
explained by chronic destabilization of HIF1α, which presides to adaptation to hypoxia and 
mediates the progression of cancer cells towards malignancy. It has been demonstrated that HIF1α 
acts as negative regulator of mitochondrial biogenesis and of oxygen consumption. Moreover, it 
also plays a pivotal role in hypoxia-related tumor radio-resistance since it is able to interfere with 
the signalling of p53, and hence to block the senescent program induced by γ-rays. The aim of this 
project was to verify whether mitochondrial biogenesis can be induced following radiation 
treatment, in relation of HIF1α status, and whether such a mechanism is predictive of a senescence 
response. In this study was demonstrate that mitochondrial biogenesis parameters like 
mitochondrial DNA copy number could be used for the prediction of hypoxic status of tissue after 
radiation treatment. γ-rays induce an increase of mitochondrial mass and function, in response to a 
genotoxic stress that pushes cells into senescence. Mitochondrial biogenesis is only indirectly 
regulated by p53, whose activation triggers a MDM2-mediated HIF1α degradation, leading to the 
release of PGC-1β inhibition by HIF1α. On the other hand, this protein blunts the mitochondrial 
response to γ-rays as well as the induction of p21-mediated cell senescence, indicating prevalence 
of the hypoxic over the genotoxic response. Finally in vivo, post-radiotherapy mtDNA copy number 
increase well correlates with lack of HIF1α increase in the tissue, concluding this may be a useful 
molecular tool to infer the trigger of a hypoxic response during radiotherapy, which may lead to 
failure of activation of cell senescence. 
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2. INTRODUCTION 
 
2.1 MITOCHONDRIA and CANCER 
 
 
2.1.1 Mitochondria origin and morphology 
 
 
Mitochondria have an endosymbiotic origin and retain many vestiges of their bacterial 
ancestry: a double membrane and a circular genome. Mitochondria resemble microbes in that they 
are typically about one micrometre in scale and constantly move, divide and fuse to form a dynamic 
network. Although mitochondria are referred to as semi-autonomous organelles, billions of years of 
expansive and reductive evolution accompanied by transfer of most of their genes to the nuclear 
genome have now effectively hard-wired these organelles within eukaryotic cells (Vafai 2012). 
Human mtDNA contains only 13 protein-coding genes, as well as the 22 tRNA and 2 ribosomal 
RNA genes required for their translation. The remaining ∼ 1100 proteins necessary for 
mitochondrial function and structure are encoded by nuclear genome. These nDNA-encoded 
mitochondrial proteins are translated on cytosolic ribosomes and selectively imported into 
mitochondrion through various mitochondrial protein import system (Wallace 2005).  
Interestingly, mtDNA has a monophyletic origin, whereas the history of the mitochondrial proteome 
is far more complex. About 400 mitochondrial proteins have a proteobacterial origin, determined by 
sequence similarity to the closest living ancestral proteobacterial species, Rickettsia prowazekii, 
other 400 proteins were obtained from other bacterial organisms (estimated by determining the 
number of mitochondrial proteins with homologues in other prokaryotic organisms) and 300 
proteins have no homologue in any prokaryotic organisms, and represent a eukaryotic innovation 
(Vafai 2012) (Fig. 1). 
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Fig. 1: Mitochondrial proteome evolution. The modern human mitochondrial proteome consists of 13 proteins, which 
are encoded by mitochondrial DNA (mtDNA) and are a vestige of the original proteobacterial genome, as well as at 
least 1,100 additional proteins that are known to be encoded by the nuclear genome (nuDNA) (Vafai 2012). 
 
The presence in the mitochondria of both an inner and outer membrane leads to the formation of 
two aqueous compartments, the matrix and inter-membrane space. The inner mitochondrial 
membrane (IMM) is the site of oxidative phosphorylation (OXPHOS), as well as numerous other 
fundamental processes, including protein import and metabolite exchange (Benard 2009). The IMM 
of mitochondria contain invaginations called cristae. The cristae are not random folds in the 
membrane but rather micro-compartments that open through narrow tubular membrane segments 
into the peripheral region of the membrane (Mannella 2008). The outer mitochondrial membrane 
(OMM) is also required for various events related to ATP generation, including the regulation of 
metabolite transport. OMM is also involved in sensing and transduction of apoptotic stimuli, both in 
stressed cells and during development. The association of various apoptosis factors, including 
proteins from the Bcl-2 family, with the OMM, makes this mitochondrial compartment a major site 
in the apoptotic signal cascade transduction (Benard 2009). The matrix harbors the majority of 
proteins including various enzymes involved in metabolic processes, such as the tricarboxylic acid 
(TCA) cycle, fatty-acid oxidation, Fe-S biogenesis, and heme synthesis. The matrix also harbors a 
number of copies of mtDNA and the protein machinery involved in its maintenance and replication 
as well as components involved in transcription/translation (Ryan 2007) (Fig. 2). 
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Fig. 2: The mitochondrial subcompartments. Examples of compartment specific processes and proteins within the 
mitochondrion  (Ryan 2007). 
 
 
2.1.2 Mitochondrial function 
 
 
The mitochondria perform four central functions in the cell: they (I) provide the majority of 
the cellular energy in the form of ATP, (II) generate reactive oxygen species (ROS), (III) regulate 
cytosolic calcium (Ca
2+
), and (IV) apoptosis through the mitochondrial permeability transition pore 
(mtPTP) (Wallace 2010).  
Energetics in animals is based on the availability of reducing equivalents, consumed as 
carbohydrates and fats. Glucose is cleaved into pyruvate via glycolysis, and the pyruvate enters the 
mitochondrion via pyruvate dehydrogenase (PDH) resulting in acetyl-CoA, NADH
+
 H
+
, and CO2. 
The acetyl-CoA then enters the TCA cycle which strips the hydrogens from hydrocarbons 
generating NADH
+
 and H
+
. Fatty acids are oxidized within the mitochondrion by beta oxidation to 
generate acetyl-CoA, NADH
+ 
plus H
+
, and FADH2. Two electrons (reducing equivalents from 
hydrogen) are transferred from NADH
+ 
 H
+
 to the OXPHOS complex NADH dehydrogenase 
(complex I) or from FADH2 containing enzymes such as the ETF dehydrogenase or succinate 
dehydrogenase (SDH, complex II) to reduce ubiquinone (coenzyme Q10, CoQ) to ubiquinol 
CoQH2. The electrons from CoQH2 are transferred successively to complex III (bc1 complex), 
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cytochrome c, complex IV (cytochrome c oxidase, COX), and finally to oxygen (½O2) to give H2O. 
The energy that is released as the electrons flow down the ETC is used to pump protons out across 
the mitochondrial inner membrane through complexes I, III, and IV creating a proton 
electrochemical gradient. The potential energy is used for multiple purposes: to import proteins and 
Ca
++ 
into the mitochondrion, to generate heat, and to synthesize ATP within the mitochondrial 
matrix. The energy to convert ADP + Pi to ATP comes from the flow of protons through the ATP 
synthetase (complex V) back into the matrix. Matrix ATP is then exchanged for cytosolic ADP by 
the inner membrane adenine nucleotide translocators (ANTs) (Wallace 2007) (Fig. 3). 
Mitochondria also regulate cellular levels of metabolites, amino acids, and cofactors for various 
regulatory enzymes, including chromatin-modifying histone deacetylases. Moreover, mitochondria 
play a central role in metal metabolism, synthesizing heme and Fe-S clusters, which are essential 
components of the major oxygen carrier, hemoglobin, as well as OXPHOS and DNA repair 
machinery (Nunnari 2012). 
 
 
 
Fig. 3 Mitochondrial physiology. Mitochondria lie at the nexus of most biosynthetic pathways, produce much of the 
cellular energy through oxidative phosphorylation (OXPHOS), regulate mitochondrial and cellular redox status, 
generate most of the reactive oxygen species (ROS), regulate Ca
2+
 concentrations and can initiate apoptosis by the 
activation of the mitochondrial permeability transition pore (mtPTP). The mtPTP can be activated by a decreased 
membrane potential, high-energy phosphates (such as ADP), a more-oxidized redox status, and/or increased 
mitochondrial matrix Ca
2+
 and ROS concentrations (Wallace 2012).  
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2.1.3 Mitochondrial network  
 
 
Mitochondrial form and function are intimately linked (Nunnari 2012). Mitochondrial 
morphologies vary widely among different cell types. Fibroblast mitochondria, for example, are 
usually long filaments (1 to 10 mm in length with a fairly constant diameter of ~700 nm), whereas 
hepatocyte mitochondria are more uniformly spheres or ovoids. Mitochondria shapes change 
continually through the combined actions of fission, fusion, and motility (Youle 2012). Large 
mitochondrial networks are frequently found in metabolically active cells. They consist of 
interconnected mitochondrial filaments and act as electrically united systems. These networks 
enable the transmission of mitochondrial membrane potential from oxygen-rich to oxygen-poor 
areas and thereby allow an efficient dissipation of energy in the cell. Similar to fusion, fission also 
plays a key role in cell life and death. As mitochondria are propagated by growth and division of 
pre-existing organelles, mitochondrial inheritance depends on mitochondrial fission during 
cytokinesis. Furthermore, mitochondrial division is important for several developmental and 
cellular differentiation processes, including the formation of synapses and dendritic spines in 
neurons and actively participates in the programmed cell death pathway (apoptosis) by inducing 
fragmentation of the mitochondrial network prior to cytochrome c release and caspase activation 
(Westermann 2008). 
Mitochondrial fusion machinery is constituted by mitofusin 1 and 2 (MFN1, MFN2) and optic 
atrophy gene 1 (OPA1). The first proteins mediate mitochondrial outer-membrane fusion while 
OPA1 regulates the same process on inner-membrane. DRP1 is recruited at sites marked by 
endoplasmatic reticulum tubules by mitochondrial fission factor (Mff) and mediates mitochondrial 
division (Nunnari 2012) (Fig. 4). 
 10 
 
 
 
Fig. 4. Steps of mitochondrial fission and fusion Schematic representation of mitochondrial fusion and fission 
pathways (Dimmer 2006). 
 
 
2.1.4 Mitochondrial genome 
 
 
In the early 1950s, yeast geneticists reported cases where the transmission of some 
mitochondrial characters did not obey Mendelian rules and followed a “cytoplasmic inheritance 
pattern”. The carrier of this non-nuclear information was called ρ (rho) and remained unknown until 
the 1960s, when the existence of mitochondrial DNA (mtDNA) molecules was formally 
demonstrated (Malka 2006).  
The human mtDNA is a circular molecule of approximately 16, 569 nucleotide pairs (nps). It retains 
the mitochondrial genes for the small (12S) and large (16S) ribosomal RNAs (rRNA) and the 22 
transfer RNAs (tRNAs) necessary to translate the 13 mtDNA polypeptides. The 13 mtDNA proteins 
are all key components of OXPHOS and include seven (ND1, ND2, ND3, ND4L, ND4, ND5, ND6) 
of the approximately 46 polypeptides of OXPHOS complex I, one (cytochrome b, cytb) of the 11 
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proteins of complex III, three (COI, COII, COIII) of the 13 proteins of complex IV, and two (ATP6, 
ATP8) of the approximately 16 proteins of complex V (Wallace 2007).  
In addition to the 37 structural genes, the mtDNA encompasses an approximately 1000 np control 
region, D-Loop. This region contains the light (L)-stand and heavy (H)-strand promoters, HSP (H1 
and H2) and LSP, respectively, the origin of H-strand replication, OH, and of L-strand, OL. The 
tRNAs punctuate the larger genes then fold in the transcripts are cleaved out to generate the 
transcripts which are then polyadenylated (Wallace 2005) (Fig. 5).  
 
 
 
 
 
 
 
Fig. 5. The human mitochondrial genome. The 37 mitochondrial DNA (mtDNA) encoded genes include seven 
subunits of complex I (ND1, 2, 3, 4, 4L, 5 and 6), one subunit of complex III (cytochrome b (Cyt b)), three subunits of 
complex IV (Cyt c oxidase (COX) I, II and III), two subunits of complex V (A6 and A8), two rRNAs (12S and 16S) 
and 22 tRNAs (one-letter code). Also shown are the origins of replication of the heavy strand (OH) and the light strand 
(OL), and the promoters of transcription of the heavy strand (HSP) and light strand (LSP) (Falkenberg 2007). 
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The studies in the field of mitochondrial genetics have unraveled a series of peculiarities and 
differences compared to the nuclear genome: 
(1) Cells are polyploid with respect to mtDNA: most mammalian cells contain hundreds of 
mitochondria and, in turn, each mitochondrion contains several (2–10) copies of mtDNA. In a given 
individual, all mtDNA copies are thought to be identical, a condition known as homoplasmy, but 
mutations can arise, be maintained or amplified to different levels and coexist with wild-type 
mtDNA, giving rise to the condition of heteroplasmy. At cell division mitochondria and their 
genomes are randomly distributed to daughter cells and hence, starting from a given heteroplasmic 
situation, different levels of heteroplasmy and even homoplasmy can arise in different cell lineages. 
As a consequence of this it is common to find a ‘threshold effect’ in mtDNA-linked human 
diseases; the mutation has to reach a certain percentage, usually higher than 60–80 %, in order to 
manifest pathological effects. 
(II) The mitochondrial genome is maternally inherited; the few mitochondria from the sperm cell 
that could enter the oocyte during fertilization are actively eliminated by ubiquitin-dependent 
mechanism. 
(III) The evolution rate of mtDNA is much faster than that of the nuclear genome. Several reasons 
are invoked to explain this fact: mtDNA is less protected by proteins, it is physically associated 
with the mitochondrial inner membrane where damaging reactive oxygen species (ROS) are 
generated, and it appears to have less-efficient repair mechanisms than the nucleus. This high 
mutation rate and the maternal inheritance pattern have made mtDNA sequence analysis an 
interesting tool in human population genetics and evolutionary studies. 
(IV) Mitochondrial genes are translated using a genetic code with some differences from the 
universal genetic code (Fernández-Silva 2003). 
It was early recognized that mtDNA does not distribute homogeneously within the mitochondrial 
compartment, but concentrates in structures that represent the dynamic and inheritable units of 
mtDNA and are called nucleoids (Malka 2006). A single nucleoid contains approximately one 
mtDNA genome packed in a space with a diameter of only 100 nm (Kukatt 2011) and a set of 
proteins involved in mtDNA replication and transcription in addition to several other metabolic 
proteins and chaperones (Bogenhagen 2008) (Fig. 6).  
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Fig. 6. Model for mtDNA nucleoid structure. Some individual mtDNA molecules within a nucleoid may be engaged 
in replication or transcription or may not be active in nucleic acid synthesis at any instant (Bogenhagen 2008). 
 
 
 
2.1.4.1 Mitochondrial DNA transcription 
 
 
Transcription originates from three promoters: two H strand promoters, called HSP1 and 
HSP2, and one L strand promoter, LSP. Transcripts emanating from HSP2 and LSP are long 
polycistronic products, some of which are nearly full-genome length. Excision of tRNAs from these 
polycistronic messengers is responsible for liberation of the mature mRNAs and rRNAs. In contrast 
to the other two promoters, transcription from HSP1 preferentially produces a relatively short 
message containing the two rRNAs and terminating at a specific site in the tRNALeu gene 
downstream of the 16S rRNA. Therefore, differential initiation at HSP1 and HSP2 determines the 
relative production of rRNAs and mRNAs from the H strand (Bonawitz 2006).  
The transcription and translation of the mitochondrial genome is dependent upon a host of nucleus-
encoded gene products. Mitochondrial DNA (mtDNA) transcription requires a single RNA 
polymerase (POLRMT), stimulatory transcription factors (Tfam, TFB2M, TFB1M), and a 
termination factor (MTERF1) (Scarpulla 2012).  
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Promoter recognition by the RNA polymerase is achieved by the insertion of a “specificity loop” 
into the DNA major groove at position −8 to −12 relative to the transcription start site. POLRMT 
may also play a role in the coordinated control of nuclear and mitochondrial transcription. In S. 
cerevisiae, there is a direct correlation between in vivo changes in mitochondrial transcript 
abundance and in vitro sensitivity of mitochondrial promoters to ATP concentration (Falkenberg 
2007).  
TFAM (mitochondrial transcription factor A) stimulates transcription through specific binding to 
the upstream enhancers on mtDNA. TFAM was first identified from human mitochondrial lysate 
fractions that stimulate the activity of crudely enriched mitochondrial RNA polymerase in LSP and 
HSP1 run off assays. This protein is highly conserved, and contains several well-defined domains, 
including an ~ 45 amino acid N-terminal mitochondrial targeting sequence (MTS), which is cleaved 
in a two-step reaction upon import to the matrix to reach a final mature product. TFAM generates 
RNAs corresponding to LSP and HSP1 initiation in these assays, which require the sequences 
immediately upstream of the transcription initiation sites. DNase I footprinting, which uses changes 
in nuclease sensitivity to map regions of protection and enhancement caused by protein binding, 
shows that TFAM binds specifically to sequences overlapping LSP and HSP1. Like other HMGB-
related protein, TFAM can bind mtDNA also in aspecific manner and is a component of nucleoids 
(Campbell 2012).  
The other two proteins essential for mtDNA transcription are TFB1M and TFB1M. Although 
TFB1M has about 1/10 the transcriptional activity of TFB2M, both proteins work together with 
TFAM and mitochondrial RNA polymerase to direct proper initiation from HSP and LSP. Both 
TFBs are also related to rRNA methyltransferases and TFB1M can bind S-adenosylmethionine and 
methylate mitochondrial 12S rRNA. Interestingly, TFB1M can also contact the carboxy-terminal 
domain of TFAM (Gleyzer 2005).   
Transcription from HSP1 preferentially terminates just downstream of the two rRNA genes 
(forming a truncated H strand transcript that encodes only the 12S and 16S rRNAs, tRNAPhe, and 
tRNAVal), whereas transcription from HSP2 typically proceeds through this termination site to 
produce a near genome-length transcript (encoding all of the mRNAs, the two rRNAs, and most of 
the tRNAs). This termination event requires a 39 kDa transcription termination factor (mTERF) that 
contains three putative leucine-zipper motifs and binds a 28 bp sequence located downstream of the 
16S rRNA gene in the tRNALeu gene (Bonawitz 2006). 
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2.1.4.2  Mitochondrial DNA replication  
 
 
Transcription from the LSP is not only necessary for gene expression, but also produces the 
RNA primers required for initiation of mtDNA replication at the origin of H-strand DNA 
replication (OH). Two modes of DNA replication have been proposed to copy the mitochondrial 
genome, an asynchronous strand displacement model and a strand-coupled bidirectional replication 
model. In the asynchronous strand displacement model, mtDNA is replicated in an asymmetric 
fashion where DNA synthesis is primed by transcription through the H-strand origin within the D-
loop. After two-thirds of the nascent H-strand is replicated, the L-strand origin is exposed, allowing 
initiation of nascent L-strand synthesis. In the strand-coupled model, bidirectional replication is 
initiated from a zone near OriH followed by progression of the two forks around the mtDNA circle 
(Kasiviswanathan 2012). MtDNA is replicated by an assembly of proteins in a replisome consisting 
of DNA polymerase γ (pol γ), the mitochondrial single-stranded DNA binding protein (mtSSB), 
mitochondrial DNA helicase, topoisomerases and RNaseH (Falkenberg 2007).  
 
 
 
2.1.5  Levels of mitochondrial-nuclear communications 
 
 
Mitochondrial-nuclear communications operate broadly at two levels. One mechanism 
involves a set of transcription factors, or coactivators, that regulate both nuclear and mitochondrial 
gene expression as occurs in response to changes in environmental temperatures, external stimuli 
such as changes in caloric intake, exercise, or changes in the levels of certain hormones such as 
thyroxine. In this mechanism, there is a change in the program of gene activation that results in the 
ability of mitochondria to undergo the synthesis and recruitment of mitochondrial and 
nonmitochondrial proteins. 
The second mechanism involves cellular responses to changes in the functional state of the 
mitochondria itself, a process also called “retrograde regulation” (Ryan 2007). 
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2.1.5.1  Nuclear-mitochondrion communication: the mitochondrial biogenesis 
 
 
Nucleus-encoded regulatory factors are major contributors to mitochondrial biogenesis and 
function. Several act within the organelle to regulate mitochondrial transcription and translation 
(example TFAM, POLG, POLRMT) while others direct the expression of nuclear genes encoding 
the respiratory chain and other oxidative functions (Scarpulla 2011). 
 
 
2.1.5.1.1 Transcription factors and coactivator acting upon the nuclear genome 
 
 
The nuclear respiratory factors, NRF-1 and NRF-2, were the first nuclear transcription 
factors implicated in the expression of multiple mitochondrial functions. NRF-1 is initially 
identified through its binding to the cytochrome c promoter and functions as a positive regulator of 
its transcription. It acts on genes encoding respiratory subunits as well as TFAM and both TFB 
isoform genes whose products are major regulators of mitochondrial transcription and ribosome 
assembly. Human NRF-2 was identified as a transcriptional activator of the cytochrome oxidase 
subunit IV (COXIV) promoter. Like NRF-1, NRF-2 participates in the expression of the 
mitochondrial protein import machinery with functional recognition sites in TOMM70 and 
TOMM20 (Fig. 7). Several additional nuclear transcription factors have been linked to the 
expression of the respiratory apparatus, including CREB, YY1 and c-myc (Scarpulla 2012 trends). 
The cAMP response element binding protein, CREB, along with NRF-1 is involved in the growth-
regulated expression of cytochrome c and both factors participate in the induction of cytochrome c 
in response to serum stimulation of quiescent cells.  
The initiator element binding factor, YY1, is engaged in both the positive and negative control of 
certain cytochrome oxidase subunit genes. YY1 recognition sites along with those for the NRFs 
were enriched among genes encoding OXPHOS subunits and assembly factors. However both YY1 
and CREB showed less specificity for respiratory genes than NRF-1 or NRF-2. Nevertheless, YY1 
has been identified as a target for the nutrient sensor mTOR and YY1 silencing in myotubules 
results in diminished mitochondrial gene expression. Finally, c-myc directs the expression of certain 
NRF-1 target genes and myc null fibroblasts are deficient in mitochondrial content (Scarpulla 2012 
b). Interestingly, c-myc positively regulates mitochondrial biogenesis and the respiratory apparatus 
through PGC-1β, an effect that is repressed by HIF1α in the absence of the von Hippel-Landau 
tumor supressor. This pathway may be part of a molecular switch from oxidative phosphorylation to 
aerobic glycolysis mediated by HIF1α in certain cancers (Zhang 2008). 
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Fig. 7:Schematic representation of mitochondrial biogenesis network. Nuclear respiratory factors (NRF-1 and NRF-
2) in the expression of nuclear genes governing mitochondrial respiratory function. NRFs act on the majority of nuclear 
genes that specify subunits of the five respiratory complexes of the mitochondrial inner membrane. In addition, they act 
on many other genes whose products direct the expression and assembly of the respiratory apparatus. Promoters for 
most of the nuclear genes encoding mtDNA transcription and replication factors have functional recognition sites for 
NRF-1, NRF-2, or both (Scarpulla 2008). 
 
The PPARγ coactivators 1 (PGC-1s) are a family of multifunctional transcriptional coactivators that 
have emerged as playing a central role in cellular and systemic metabolism. The first member of the 
PGC-1family, PGC-1α, was initially identified as a transcriptional coactivator driving 
mitochondrial function and thermogenesis in brown fat. The two other family members, PGC-1β 
and PGC-1 related coactivator (PRC) were discovered using sequence homology searches (Girnun 
2012) (Fig. 8). The PGC-1 coactivators contain a conserved N-terminal domain that interacts with 
proteins capable of remodeling chromatin, including histone acetyl transferases, such as CREB-
binding protein, p300, and steroid receptor coactivator 1. This chromatin remodeling allows access 
to additional factors that enhance transcription. 
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The C-terminal domain of PGC-1 binds a second activating complex, consisting of the steroid 
hormone receptor-associated protein, TRAP/DRIP, and containing an RNA-binding domain that 
facilitates pre-mRNA splicing (Ryan 2007). 
 
 
 
 
 
Fig. 8: PGC-1 family coactivator. Schematic comparison of PGC-1α, PGC-1β and PRC with the identities of the 
conserved sequence motifs shown in the key at the bottom. All three PGC-1 members are characterized  by an N-terminal 
activation domain near leucine-rich LXXLL motifs that mediate interaction with nuclear receptors, an RNA recognition 
domain (RRM), and a host cell factor-1 (HCF) binding domain. In addition, PGC-1a contains an RNA splicing domain (RS), 
the function of which has not been fully defined (Scaruplla 2012 c). 
 
 
The three family members are differentially regulated by environmental cues governing pathways 
of thermogenesis, gluconeogenesis, muscle differentiation, and cell growth. The coactivators, in 
turn, implement programs of gene expression through direct interaction with transcription factor 
targets or through their indirect effects on transcription factor expression (Scarpulla 2008) (Fig. 9). 
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Fig. 9: Control of mitochondrial biogenesis by PGC-1. Interaction between PGC-1 and specific transcription factors 
orchestrates the major functions of mitochondria, including fatty acid b-oxidation, the tricarboxylic acid cycle (TCA), 
mtDNA replication and oxidative phosphorylation, and the electron transport chain (OxPhos/ETC), in addition to 
biogenesis of this organelle. PPARa interacts with its binding partner, the retinoid X receptor (RXR), to control the 
expression of many fatty acid b-oxidation enzymes. NRF-1 and NRF-2 contribute to the maintenance of mtDNA and 
the expression of multiple components of the ETC. ERR members regulate the expression of virtually all functions of 
the mitochondria including those shown here (Scarpulla 2012). 
 
 
PGC-1α lacks histone-modifying enzymatic activities but it interacts, through a potent amino-
terminal activation domain, with a number of coactivator complexes which contain intrinsic 
chromatin remodeling activities (SRC-1, CBP/p300 and GCN5). In addition PGC-1α binds a large 
complement of transcription factors and nuclear hormone receptors. Among those directly 
associated with mitochondrial respiratory function are NRF-1, YY1, PPARα and MEF2C. PGC-1α 
can trans-activate NRF-1 target genes and a dominant negative allele of NRF-1 blocks the effects of 
PGC-1α on mitochondrial biogenesis. The proposed role for PGC-1α as a regulator of 
mitochondrial biogenesis is supported by gain of function experiments in both cultured cells and 
transgenic mice. In cultured cells, ectopic PGC-1α expression increases COXIV and cytochrome c 
protein levels as well as the steady-state level of mtDNA. More recently, metabolic signaling 
through PGC-1α was found to occur through post-translational modifications. For example, AMP-
activated protein kinase (AMPK), an enzyme sensor that is activated upon energy depletion in 
muscle, phosphorylates PGC-1α on specific serine and threonine residues. This results in increased 
mitochondrial gene expression supporting the idea that AMPK can mediate at least some of its 
effects through PGC-1α (Scarpulla 2011).  
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A homologue of PGC-1α was designated as PGC-1β. PGC-1α and β are closely related but PGC-1β 
lacks the arginine/serine (R/S) domain that is associated with RNA processing. PGC-1β appears 
identical to PGC-1α in its functional interaction with NRF-1 and in its ability to promote the 
expression of nuclear respiratory genes and mitochondrial mass when expressed from viral vectors. 
Interestingly, despite the functional similarities between the two family members, PGC-1β 
promotes a much higher level of coupled respiration than PGC-1α, suggesting differences between 
the two in metabolic efficiency (Scarpulla 2011).  
While PGC-1β expression in distinct tissues is unaffected by physiological processes characterized 
by increased energy expenditure, such as cold exposure (in brown adipose tissue), fasting (in liver) 
or exercise (in muscle), PGC-1α is highly regulated at the transcriptional level under similar 
physiological challenges. These data suggest that PGC-1β likely controls basal mitochondrial 
biogenesis, whereas PGC-1α controls stimulated or regulated mitochondrial activity. Moreover 
PGC-1β is a regulator of mitochondrial fusion, promoting Mfn2 expression (Liesa 2008). 
PRC was identified as a large cDNA with significant sequence similarities to PGC-1α within the 
carboxy-terminal RS domain and RNA recognition motif. PRC shares with PGC-1α and β the 
ability to bind NRF-1 both in vitro and in vivo and to use NRF-1 for the trans-activation of NRF-1 
target genes. NRF-1-dependent trans-activation requires the PRC activation domain, suggesting that 
this domain shares function with PGC-1α in recruiting chromatin-remodeling cofactors that drive 
transcription. PRC and PGC-1α are indistinguishable in trans-activating promoters for cytochrome 
c, 5-aminolevulinate synthase, and both of the TFB isoforms, suggesting that PRC may participate 
in the expression of the respiratory chain. Maximal trans-activation by both coactivators requires 
the NRF-1 and NRF-2 binding sites within the proximal promoters of these genes. Although similar 
to PGC-1α in these basic transcriptional properties, PRC mRNA is not enriched in brown versus 
white fat and is only slightly elevated in brown fat upon cold exposure, arguing against a major role 
for PRC in adaptive thermogenesis. Analysis of PRC expression in cultured fibroblasts revealed 
that PRC levels correlate with the cell proliferative cycle. The steady-state expression of PRC 
mRNA and protein is high in growing cells but markedly diminished upon exit from the cell cycle 
as a consequence of contact inhibition or serum withdrawal (Scarpulla2008).  
The external stimuli, which influence mitochondrial function, are sensed in various ways by 
different tissues. This leads to the activation of signal transduction pathways that allow tissue-
specific activation of PGC-1 transcription. For example, cold exposure leads to the activation of β-
adrenergic receptors in brown adipose tissue cells, activating the cAMP pathway to transcriptional 
activation of PGC-1α and downstream expression of UCP1, thereby leading to uncoupled 
thermogenesis. Long-term exercise in mice, by contrast, leads to chronic energy deficits, which are 
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sensed by AMP-activated protein kinase (AMPK), which in turn leads to mitochondrial biogenesis 
via calcium/calmodulindependent protein kinase (CaMK) and PGC-1α. Nitric oxide was also 
implicated as a signaling molecule in PGC-1α induction via a cGMP-dependent mechanism in a 
wide range of cell types. Transgenic mice with deficient epithelial nitric oxide synthase were 
deficient in mitochondrial biogenesis. Likewise, the transcription of PGC-1α was regulated through 
the release of repression by p160 through p38 MAP kinase. Thyroid (T3) and glucocorticoid 
hormones also induce mitochondrial biogenesis and respiration (Ryan 2007). 
Interestingly, an increase of mitochondrial biogenesis was observed in cell treated with 
chemotherapic drugs (Fu 2008, Kluza 2004). 
  
 
2.1.5.2  Mitochondrial-nuclear communication: the  retrograde signal 
 
  
Metabolic cues or other damage that occurs within mitochondria can culminate in wide 
range of changes in nuclear gene expression via retrograde signaling from the mitochondria to the 
nucleus. Altered nuclear gene expression in response to mitochondrial dysfunction in mammalian 
cells was suggested by studies showing increased mRNA levels coding for various mitochondrial 
proteins in different ρ° cell lines. Mitochondrial retrograde signaling in mammalian cells (also 
referred to as mitochondrial stress signaling) was described initially in C2C12 skeletal myoblasts 
(rhabdomyoblasts) and later confirmed in human lung carcinoma A549 cells. Mitochondrial stress 
was defined by altered mitochondrial membrane potential, Δψm, induced either by treating cells 
with ethidium bromide to partially deplete their mtDNA content or with the mitochondria-specific 
ionophore, CCCP (carbonyl cyanide m-chlorophenyl hydrazone) (Butow 2004). These treatments 
result in the elevation of cytosolic Ca
2+
  and activation of CaMK and calcineurin-responsive genes. 
Such responses appear to be mediated through PGC-1α. Thus, overexpression of CaMK in muscle 
of transgenic mice resulted in generalized increases in mitochondrial biogenesis and fatty-acid 
oxidation. In cultured myocytes, CaMK was capable of inducing PGC-1 transcription through a 
direct effect on the gene promoter. This activation is dependent on MEF2-responsive elements in 
the case of calcineurin A and on the CREB-binding site in the case of CaMK. The genes activated 
by these changes in Ca
2+
 levels include a number of genes involved in Ca
2+
 transport and storage as 
well as a large number of transcription factors. The general net effect of activation of this gene 
network is to facilitate recovery of physiological function (Ryan 2007) (Fig. 10).  
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Fig. 10: Retrograde signaling in mammalian cells. Retrograde signaling in mammalian cells Occurs through 
Increased Cytosolic Ca
2+
Disruption of Δψm by various causes affects mitochondrial uptake of Ca
2+
 and reduced efflux 
into storage organelles or outside the cells due to reduced availability of ATP. Increased cytosolic Ca
2+
 in turn activates 
calcineurin and various Ca
2+
-dependent kinases (Butow 2004). 
 
 
Mitochondria also appear to have a stress response pathway superficially similar to the unfolded 
protein response in the endoplasmic reticulum. The accumulation of a mutant form of misfolded 
ornithine transcarbamylase (OTC) in the mitochondrial matrix induces a stress response that 
activates CEBP homology protein, CHOP, and induces expression of nuclear gene-encoded stress 
response proteins, Cpn60, Cpn10, mtDNAJ, and ClpP (Butow 2004).  
 
 
2.1.6 Mitochondria and diseases  
 
 
A broad spectrum of complex clinical phenotypes has been linked to mutations in nDNA and 
mtDNA mitochondrial genes. Very different gene mutations can cause a similar range of 
phenotypes, mutations in the same gene can give a range of different phenotypes, and the same 
mtDNA mutation at different levels of heteroplasmy can result in totally different phenotypes 
(Wallace 2010). 
Accordingly, mitochondrial disorders are a complex dual genome disease that can be caused by 
molecular defects in both nuclear and mitochondrial genomes. The disease is genetically 
heterogeneous. Depending upon the primary defect, mitochondrial disorders may be autosomal 
recessive, autosomal dominant, X-linked, or maternally inherited (Wong 2010). 
Most often, mitochondrial diseases are caused by molecular defects affecting OXPHOS system, i.e. 
electron transport chain complexes which perform oxidative phosphorylation (Fig. 11). 
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Fig. 11: List of genes that are known to be mutated in respiratory chain disorders grouped by pathway (Shon 2012) 
 
Although mitochondrial oxidative phosphorylation (OXPHOS) disorders are quite varied, they 
typically display a number of ‘canonical’ biochemical and morphological features. An obvious 
feature is respiratory chain deficiency, which typically manifests itself as reduced enzymatic 
function in one or more respiratory chain complexes, with a concomitant reduction in cellular 
oxygen consumption and ATP synthesis. In addition, patients often have increased resting lactic 
acid levels in the blood. Under normal conditions, pyruvate (the end product of anaerobic 
glycolysis) is transported into mitochondria for further oxidation in the TCA cycle to produce the 
reducing equivalents (namely, NADH and FADH
2
) that are required for proton pumping by the 
respiratory chain. However, if the respiratory chain is compromised, NADH and pyruvate 
accumulate in the cytosol. Excess cytosolic pyruvate is converted to lactate by lactate 
dehydrogenase, thereby accounting for the increased lactic acid found in many mitochondrial 
diseases and especially in those affecting infants or young children. A prominent morphological 
feature of OXPHOS disease is the ragged red fibre (RRF), which reflects a massive proliferation of 
OXPHOS-defective mitochondria in muscle; this can be visualized with the modified Gomori 
trichrome stain (Schon 2012) (Fig. 12). 
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Fig. 12: Ragged red fibre seen on a modified Gomori-trichrome-stained skeletal-muscle section (Vafai 2012) 
 
 
 
The vast majority of OXPHOS mutations impair the cell’s ability to produce ATP in amounts that 
are sufficient for maintaining viability, but sometimes OXPHOS problems can leave ATP synthesis 
intact and yet can be deleterious by, for example, stimulating the overproduction of reactive oxygen 
species (ROS) or inducing an autoimmune response (Schon 2012). 
Mitochondrial diseases are caused also by mutation in genes involved in mitochondrial biogenesis 
and mtDNA maintenance and expression (ex. POLG and mt-tRNA) , fusion and fission (ex. OPA1) 
(Wallace 2010).  
Since mitochondria are the essential energy-producing organelles in animal cells, virtually all organ 
systems may be affected if there is a mitochondrial defect. However, the tissues with high-energy 
demand, such as muscle and nerve, are most susceptible. In general, neuromuscular symptoms are 
the major clinical features of mitochondrial diseases, including seizures, skeletal muscle weakness, 
exercise intolerance, cardiomyopathy, sensorineural hearing loss, optic atrophy, retinitis 
pigmentosa, ophthalmoplegia, diabetes mellitus, hypothyroidism, gastrointestinal reflux, renal 
dysfunction, and immunodeficiency (Wong 2010) (Fig. 13). 
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Fig. 13: Common clinical manifestations of mitochondrial disorders (Shown 2012). 
 
 
 
2.1.7 Mitochondria and cancer 
 
 
2.1.7.1  Tumor metabolism 
 
 
In 2000, the Hanahan and Weinberg’s groups proposed the hallmarks of cancer that 
comprised six biological capabilities acquired during the multistep development of human tumors. 
They include sustaining proliferative signaling, evading growth suppressors, resisting cell death, 
enabling replicative immortality, inducing angiogenesis, and activating invasion and metastasis. 
Underlying these hallmarks are genome instability, which generates the genetic diversity that 
expedites their acquisition, and inflammation, which fosters multiple hallmark functions. But, 
conceptual progress in the last decade has added two emerging hallmarks of potential generality to 
this list: evading immune destruction and reprogramming of energy metabolism (Hanahan 2011). 
The relation between metabolism and cancer dates back to 1924 when Otto Warburg observed that 
cancer cells metabolize glucose in a manner that is distinct from that of cells in normal tissues. Our 
current understanding of metabolic pathways is based largely on studies of nonproliferating cells in 
differentiated tissues. In the presence of oxygen, most differentiated cells primarily metabolize 
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glucose to carbon dioxide by oxidation of glycolytic pyruvate in the mitochondrial TCA cycle. This 
reaction produces NADH [nicotinamide adenine dinucleotide (NAD
+
), reduced], which then fuels 
oxidative phosphorylation to maximize ATP production, with minimal production of lactate. It is 
only under anaerobic conditions that differentiated cells produce large amounts of lactate. In 
contrast, most cancer cells produce large amounts of lactate regardless of the availability of oxygen 
and hence their metabolism is often referred to as “aerobic glycolysis.” Warburg originally 
hypothesized that cancer cells develop a defect in mitochondria that leads to impaired aerobic 
respiration and a subsequent reliance on glycolytic metabolism. However, subsequent work showed 
that mitochondrial function is not impaired in most cancer cells suggesting an alternative 
explanation for aerobic glycolysis in cancer cells (Vander Heiden 2009) (Fig. 14). 
 
 
Fig. 14: Schematic representation of the differences between oxidative phosphorylation, anaerobic glycolysis, 
and aerobic glycolysis (Warburg effect). In the presence of oxygen, nonproliferating (differentiated) tissues first 
metabolize glucose to pyruvate via glycolysis and then completely oxidize most of that pyruvate in the mitochondria to 
CO2 during the process of oxidative phosphorylation. Because oxygen is required as the final electron acceptor to 
completely oxidize the glucose, oxygen is essential for this process. When oxygen is limiting, cells can redirect the 
pyruvate generated by glycolysis away from mitochondrial oxidative phosphorylation by generating lactate (anaerobic 
glycolysis). This generation of lactate during anaerobic glycolysis allows glycolysis to continue (by cycling NADH 
back to NAD+), but results in minimal ATP production when compared with oxidative phosphorylation. Warburg 
observed that cancer cells tend to convert most glucose to lactate regardless of whether oxygen is present (aerobic 
glycolysis). This property is shared by normal proliferative tissues. Mitochondria remain functional and some oxidative 
phosphorylation continues in both cancer cells and normal proliferating cells. Nevertheless, aerobic glycolysis is less 
efficient than oxidative phosphorylation for generating ATP. In proliferating cells, ~10% of the glucose is diverted into 
biosynthetic pathways upstream of pyruvate production (Vander Heiden 2009). 
 
 27 
 
Cancer cells synthesize great amounts of nucleotides, macromolecules and lipids, and these 
biosynthesis require continuous production of NAD
+
, NADPH
+
 and ATP. They consume at least 10 
times more glucose than normal cells and produce lactic acid, even in the presence of oxygen. High 
rates of glucose uptake have been clinically used to detect tumours by positron emission 
tomography with a glucose analogue tracer (PET) (Icard 2012). 
Glycolysis is inefficient in terms of ATP production, as it generates only two ATP molecules per 
molecule of glucose, whereas complete oxidation of one glucose molecule by oxidative 
phosphorylation can generate up to 36 ATP molecules. This raises the question of why a less 
efficient metabolism, at least in terms of ATP production, would be selected for in proliferating 
cells (Vander Heiden 2009). 
Despite its low efficiency in ATP yield per molecule of glucose, aerobic glycolysis can generate 
more ATP than oxidative phosphorylation by producing ATP at a faster rate. Provided the glucose 
supply is abundant, an inefficient but faster pathway for ATP production may be preferred to meet 
the high demands of dividing cells. However, glycolysis is not the major contributor of ATP in 
most cells: a compilation of data for 31 cancer cell lines/tissues from studies that determined 
oxidative ATP production (by measuring O2 consumption) and glycolytic ATP production (by 
measuring lactate excretion) shows that the average percentage of ATP contribution from glycolysis 
is 17%. This collection of data does not support the hypothesis that cancer cells exhibit aerobic 
glycolysis to generate ATP faster (Lunt 2011). 
Advantages which glycolytic metabolism conveys to cancer cells include supply of nucleotides for 
DNA synthesis, lipids for membrane biogenesis and glutathione for redox regulation. Therefore, a 
main function of upregulated glycolysis in proliferating cells may be to maintain the levels of 
glycolytic intermediates needed to support biosynthesis (Icard 2012).  
DNA and RNA, which are composed of nucleotides, account for a significant portion of cell mass. 
Each purine nucleotide (ATP, GTP, dATP, and dGTP) synthesized by the cell requires the 
assimilation of 10 carbon atoms from the extracellular environment. Half of the purine nucleotide 
carbons are derived from 5-phosphoribosyl-α-pyrophosphate (PRPP), an activated version of 
ribose-5-phosphate, which ultimately is derived from carbohydrate nutrients. Glucose is the major 
carbohydrate available to most animal cells. The activity of PRPP synthetase, an enzyme that 
converts ribose-5-phosphate to PRPP, increases two- to tenfold in lymphocytes following mitogen 
stimulation, which highlights the importance of increased PRPP generation for nucleotide 
biosynthesis during cell growth. In addition to serving as building blocks of nucleic acids, purines 
are necessary for cofactor biosynthesis, as adenine is present, for example, in FAD(H2) (flavin 
adenine dinucleotide, reduced), NAD(H), NADP(H), and coenzyme A (CoA). Glycolysis is also a 
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major source of carbons for biosynthesis of pyrimidine nucleotides, as the majority (five out of 
nine) of the carbons comes from PRPP. In addition to supporting nucleotide biosynthesis, glycolysis 
is also a source of carbon for lipid precursors. The glycolytic intermediate dihydroxyacetone 
phosphate is the precursor to glycerol-3-phosphate, which is crucial for the biosynthesis of the 
phospholipids and triacylglycerols that serve as major structural lipids in cell membranes. Elevated 
levels of glycerol and glycerol-3-phosphate have been reported in human peripheral lymphocytes 
after mitogen stimulation, and elevated levels of choline phospholipids have been found in breast 
cancer (Lunt 2011) (Fig. 15).  
 
Fig. 15: Metabolic pathways active in proliferating cells. This schematic represents our current understanding of how 
glycolysis, oxidative phosphorylation, the pentose phosphate pathway, and glutamine metabolism contribute to biomass 
precursors. Enzymes that control critical steps and are often overexpressed or mutated in cancer cells are shown in dark 
blue. Nucleotides that can be incorporated into DNA and RNA are highlighted in light blue, representative lipids are 
highlighted in green, and nonessential amino acids are highlighted in orange (Lunt 2011) 
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Glutamine was recognized as another highly demanded cancer cell nutrient, sometimes indicated to 
be even more essential than glucose. Glutamine, which circulates with the highest concentration 
among amino acids, serves as a major bioenergetic substrate and nitrogen donor for proliferating 
cells. Glutamine enters into the TCA via its conversion to glutamate and then to a-ketoglutarate 
(aKG), a key TCA cycle intermediate that is also a cofactor for dioxygenases (Dang 2012).  
Despite the dependence of tumor on glucose and glutamine metabolism, the presence of functional 
mitochondria is essential for the cancer cell. This was confirmed by the elimination of mtDNA from 
various cancer cells through growth in ethidium bromide (Rho0 cells). The resulting Rho0 cancer 
cells have reduced growth rates, decreased colony formation in soft agar and markedly reduced 
tumor formation in nude mice (Wallace 2012).  
 
2.1.7.2 Tumor microenvironment: hypoxia and HIF1α 
 
Together with elevated energy demand and building block requirements, the main selective 
pressure for metabolism regulation during any solid cancer progression is hypoxia. A critical 
difference between the tumor microenvironment and that of the surrounding normal tissue is the 
presence of intratumoral hypoxia (Semenza 2012). Hypoxia in tumors is primarily a 
pathophysiologic consequence of structurally and functionally disturbed microcirculation and the 
deterioration of diffusion conditions. Tumor hypoxia appears to be strongly associated with tumor 
propagation, malignant progression, and resistance to therapy and it has thus become a central issue 
in tumor physiology and cancer treatment (Höckel 2001).  
Crucial mediators of the hypoxic response are the HIFs transcription factors, which transactivate a 
large number of genes including those promoting angiogenesis, anaerobic metabolism and 
resistance to apoptosis. HIFs are heterodimers comprising one of three major oxygen labile HIFα 
subunits (HIF1α, HIF2α or HIF3α), and a constitutive HIF1β subunit (also known as aryl 
hydrocarbon receptor nuclear translocator or ARNT), which together form the HIF1α, HIF2α and 
HIF3α transcriptional complexes, respectively. Of the three α-subunits, HIF1α and HIF2α are the 
best studied. HIF3α has high similarity to HIF1α and HIF2α in the basic helix–loop–helix (bHLH) 
and Per-Arnt-SIM (PAS) domains, but lacks the C-terminal transactivation domain (TAD-C). 
HIF3α has multiple splice variants, the most studied being the inhibitory PAS domain protein 
(IPAS), which is a truncated protein that acts as a dominant negative inhibitor of HIF1α. HIF1α and 
HIF2α have 48% amino acid sequence identity and similar protein structures, but are nonredundant 
and have distinct target genes and mechanisms of regulation (Fig. 16) (Koh 2012).  
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Fig. 16: The structural domains of hypoxia-inducible factor (HIF)-1/2/3a and their transcriptional binding partner, HIF-
1b/ARNT (aryl hydrocarbon nuclear translocator), that together form the HIF1, HIF2 and HIF3 transcriptional 
complexes, respectively (Koh 2012). 
 
Interesting, it appears that in some cell lines, HIF1α is most active during short periods (2–24 h) of 
intense hypoxia or anoxia (<0.1% O2), whereas HIF2α is active under mild or physiological 
hypoxia (<5% O2), and continues to be active even after 48–72 h of hypoxia. Hence, in certain 
contexts, HIF1α drives the initial response to hypoxia, but during chronic hypoxic exposure, it is 
HIF2α that plays the major role in driving the hypoxic response (Koh 2012).  
Using molecular oxygen (O2) and 2-oxoglutarate as substrates, hypoxia-inducible factor (HIF) 
prolyl-hydroxylase (PHD) enzymes hydroxylate two specific proline residues in the O2-dependent 
degradation domain (ODD) of HIFα proteins. These hydroxylation events occur on Pro402 and 
Pro564 in HIF1α, and Pro405 and Pro531 in HIF2α, and are required for the von Hippel–Lindau 
(VHL) tumour suppressor protein (the recognition component of an E3 ubiquitin ligase complex) to 
bind and degrade HIFα subunits under normoxic conditions. Hypoxia inhibits PHD activity through 
various mechanisms, including substrate limitation, which results in HIFα subunit stabilization, 
heterodimerization with HIF1β and increased HIF transcriptional activity. Hypoxic conditions also 
inhibit hydroxylation by factor inhibiting HIF (FIH) of a conserved carboxy-terminal asparagine 
residue in the HIFα subunits, an event that blocks the interaction between HIFα subunits and the 
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transcriptional co-activators p300 and CREB binding protein (CBP). Thus, whereas PHD-mediated 
hydroxylation destabilizes HIFα subunits, FIH-mediated hydroxylation inhibits their transcriptional 
activity (Keith 2011).  
Under hypoxic conditions, PHD activity is inhibited, pVHL binding is abrogated, and HIF1α and 
HIF2α are stabilized. HIF1/2α enter the nucleus, where they heterodimerize with HIF1β and bind to 
a conserved DNA sequence known as the hypoxia responsive element (HRE), to transactivate a 
variety of hypoxia-responsive genes (Fig. 17) (Semenza 2003). 
 
 
 
Fig. 17: Genes that are transcriptionally regulated by HIF (Semenza 2003).  
 
Immunohistochemical analyses revealed that HIF1α is overexpressed in many human cancers. 
Significant associations between HIF1α overexpression and patient mortality have been shown in 
cancers of the brain (oligodendroglioma), breast, cervix, oropharynx, ovary and uterus 
(endometrial). In fact HIF1α activity leads to upregulation of genes that are involved in many 
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aspects of cancer progression, including metabolic adaptation, apoptosis resistance, angiogenesis 
and metastasis (Fig. 17).  
One way in which HIF1α promotes cell survival under hypoxic conditions is by mediating a switch 
from oxidative to glycolytic metabolism. The transcription factor HIF1α induces glycolysis under 
low oxygen tension through the upregulation of genes encoding glucose transporters, glycolytic 
proteins and angiogenic factors (such as erythropoietin and vascular endothelial growth factor 
(VEGF), and the inhibition of mitochondrial function. HIF1α affects mitochondria by various 
mechanisms: it induces PDHK1, thus inhibiting PDH and retarding the conversion of pyruvate to 
mitochondrial acetyl-CoA; it induces the low oxygen tension subunit of complex IV, COX4-2; it 
upregulates the mitochondrial LON protease to degrade the normoxic subunit, COX4-1; it activates 
mitophagy to degrade existing mitochondria; and it inhibits MYC signaling that regulate the 
mitiochondrial coactivator PGC-1β. HIF1α also upregulates the transcription of miR-210, which 
downregulates mitochondrial metabolism by inhibiting expression of the ISCU1 and ISCU2 genes 
which encode proteins involved in iron sulphur centre synthesis and genes for subunits of complex I 
(NDUFA4), complex II (SDHD) and complex IV (COX10). Finally, HIF1α mediates the 
transcription of PKM2, but not PKM1, and PKM2 also serves as a co-transcriptional activator of 
HIF1α. This is mediated by PHD3, which hydroxylates prolines 403 and 408 of PKM2, thus 
enhancing the binding of PKM2 to HIF1α (Wallace 2012).  
 
2.1.7.3 Role of mitochondria in tumorigenesis 
 
As mitochondria play a critical role in numerous bioenergetic, anabolic and cell death-inducing 
biochemical pathways, it is not surprising that mitochondrial dysfunction contributes to the 
development of a plethora of human diseases, which range from highly tissue-specific conditions to 
generalized whole-body disorders including cancer. Several common features of established tumor 
cells can directly or indirectly result from mitochondrial deregulation. Moreover, mitochondria may 
be implicated in early tumorigenesis, as cancer progenitor cells appear, replicate and progressively 
acquire a malignant phenotype (Galluzzi 2010).  
Although mutations in the mtDNA in cancer cells have been recognized for more than two decades, 
interest in the role of mitochondrial alterations in cancer came to general attention with the 
discovery of mitochondrial tricarboxylic acid (TCA) cycle gene mutations in cancer cells. Cancer 
cell defects are now well established in the genes for succinate dehydrogenase (SDH), fumarate 
hydratase (FH), and isocitrate dehydrogenase 1 (IDH1) and IDH2 (Wallace 2012).  
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Specifically, mutations in fumarate hydratase were found in families afflicted with leimyomatosis 
and kidney cancers, and mutations in succinate dehydrogenase were found in patients with 
pheochromocytoma and paragangliomas. These mutations cause a disruption of the TCA cycle with 
the accumulation of fumarate or succinate, both of which can inhibit prolyl hydrolases that mediate 
the degradation of HIFs proteins (Jones 2009). Heterozygous missense mutations in the two 
NADP+-dependent IDH enzymes, cytosolic IDH1 and mitochondrial IDH2, have been observed in 
gliomas, astrocytomas, chondromas and acute myeloid leukaemia (AML). IDHs are homodimer 
enzymes, and the cancer cell mutations identified to date create a neomorphic function. Like IDH3, 
IDH1 and IDH2 can oxidatively decarboxylate isocitrate to α-ketoglutarate. However, IDH1 and 
IDH2 reduce NADP+ instead of NAD+, and the NADP+-dependent reaction is reversible because 
NADPH can provide sufficient energy to drive the reductive carboxylation of α-ketoglutarate to 
isocitrate. However, the neomorphic IDH1-R132 and IDH2-R172 mutants use NADPH to reduce 
α-ketoglutarate to R(-)-2-hydroxyglutarate ((R)-2HG). As a result, IDH1 and IDH2 mutant cancers 
produce 10–100-fold increased levels of (R)-2HG64, which has been hypothesized to be an 
‘oncometabolite’. (R)-2HG is associated with alterations in cellular genomic methylation and 
transcription patterns and is a potent inhibitor of the α-ketoglutarate-dependent Jumonji-C domain 
histone Nε-lysine demethylases (JMJD2A, JMJD2C and JMJD2D (also known as KDM4D)). 
Hence, (R)-2HG may act by altering chromatin modifications. The target genes showing marked 
changes include transforming growth factor-β (TGFβ), RAS, epidermal growth factor receptor 
(EGFR), WNT and genes in angiogensis pathways. As the WNT pathway, among others, has been 
implicated in the regulation of mitochondrial energy metabolism, such global changes in chromatin 
structure could accompany alterations in bioenergetics (Wallace 2012).  
Genes encoded by mitochondrial DNA (mtDNA) have long been suspected to be actively involved 
in tumorigenesis when cells require high amounts of energy to grow and proliferate under few 
constraints (Gasparre 2011). Somatic and germline mtDNA mutations have been reported for a 
wide variety of cancers. These include renal adenocarcinoma, colon cancer cells, head and neck 
tumours, astrocytic tumours, thyroid tumours, breast tumours, ovarian tumours, prostate and 
bladder cancer (Fig. 18) (Chatterjee 2006). Ancient mtDNA population variants have also been 
correlated with cancer risk. For example, the macrohaplogroup N variant in the complex I, subunit 
ND3 gene (ND3; also known as MTND3) at nucleotide G10398A (resulting in a T114A amino acid 
change) has been associated with breast cancer risk in African American women, and the 16519 T 
to C mtDNA control region variant is associated with endometrial cancer. A mtDNA cytochrome c 
oxidase subunit 1 (CO1; also known as MTCO1) T6777C nucleotide variant has been linked with 
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epithelial ovarian cancer, along with variants in several nDNA mitochondrial genes (Wallace 2012). 
Furthermore, the mechanistic role played by these mutations is far from being elucidated 
 
 
 
 
Fig. 18: The mitochondrial genome showing the various mutations summarized in this review. For mutations in 
complex I (ND1, ND2, ND3, ND4, ND5, ND6 and ND4L), in complex III (Cyt B), in complex IV (COX I, COX II and 
COX III), mutations in complex V (ATPase 6) (Chatterjee 2006). 
 
The most credited hypothesis is that they may foster tumor progression in various ways such as 
through effects on regulation of apoptosis, hypoxia-inducible factor-1α (HIF1α) stabilization, and 
reactive oxygen species (ROS) production and hence metastatic potential. Recently, Gasparre and 
colleagues have demonstrated that the oncogenic properties of a mtDNA encoded CI gene to 
influence tumor growth depend by the levels of heteroplasmy of such mutations. 
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2.1.7.4 Oncocytic tumors 
 
 
Oncocytic tumors are a subset of neoplasia characterized by a major component of cells with 
aberrant mitochondrial hyperplasia (Fig. 18); they mainly originate from epithelial tissue and occur 
more frequently in endocrine organs such as the thyroid, kidney, parotid, parathyroid and pituitary 
glands (Gasparre 2010). Such peculiar type of cancer has been taken up as an excellent model to 
study the role of mitochondrial metabolism and of mitochondrial DNA (mtDNA) mutations in 
tumor progression. In fact, mitochondrial function is strongly hampered in oncocytic cells (Bonora 
2007) and this has been ascribed to what is nowadays well ascertained to be the genetic hallmark of 
oncocytic tumors, namely the high frequency of deleterious mtDNA mutations, particularly in 
complex I genes (Gasparre 2007, Porcelli 2010).  
 
Fig. 19: Histologic appearance of the hyperplastic oncocytic nodule (A) and of one hyperplastic nodule without 
oncocytic change (B) (Gasparre 2007). 
 
Upon the dissection of the functional consequences of such mutations, oncocytic tumors have 
revealed one of the determinants of their mostly benign behaviour, namely the setting in of a 
pseudonormoxic situation, i.e. a chronic hypoxia-inducible factor 1a (HIF1α) destabilization, due to 
an imbalance of α-ketoglutarate and succinate, two key Krebs cycle metabolites which regulate the 
prolyl-hydroxylases responsible for HIF1α degradation (Porcelli 2010, Gasparre 2012). HIF1α is 
well known to be the main transcription factor presiding to adaptation to hypoxia and mediating the 
progression of cancer cells towards malignancy (Semenza 2003), whose destabilization in oncocytic 
tumors may explain the low-proliferative and low-aggressive behaviour. In fact, oncocytic tumors 
are often considered benign entities, which may be in part due to the scarce ability to trigger 
neoangiogenesis, a feature that aids differential diagnosis, for instance, in renal oncocytoma 
(Gasparre 2010).  
Recently, a parotid and a thyroid oncocytoma were described in patients with PTEN and FLCN 
mutation, causing autosomal dominant syndromes, respectively Cowden and Birt–Hogg–Dubè, 
(Pradella 2013), suggesting that there could be an alternative determinant to pathogenic mtDNA 
mutation in oncocityc phenotype in cancer cells. 
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Interestingly, oncocytic tumors have been described to be more resistant to radiotherapy than their 
non-oncocytic counterparts, consistently with the reports that rectal carcinoma patients undergoing 
radiotherapic treatment were observed to develop oncocytic relapses in the same anatomical site of 
the primary tumor (Rouzbahman 2006, Ambrosini-Spaltro 2006). 
 
 
 
2.2  P53: LINK BETWEEN CANCER METABOLISM AND DNA DAMAGE RESPONSE 
 
 
2.2.1 p53 and mitochondria  
 
 
The tumor suppressor p53 can mediate growth arrest and initiate apoptosis.  In addition to its 
traditional role of guardian of the genome, p53 appears to regulate various aspects of metabolism 
and mitochondrial biogenesis. It can be phosphorylated by AMP-activated protein kinase (AMPK) 
in response to energy limitation, thus activating cell cycle checkpoints. p53 also favours ATP 
production by OXPHOS and the decrease of cellular ROS production by inducing TP53-induced 
glycolysis and apoptosis regulator (TIGAR). TIGAR negatively regulates glycolysis by degrading 
fructose-2,6-bisphosphate, which is an allosteric activator of phosphofructokinase 1. This shifts 
carbon flux away from glycolysis and into the pentose phosphate pathway, which increases 
NADPH production and thus heightens antioxidant defences. p53 also negatively regulates 
phosphoglycerate mutase and AKT, thus further inhibiting glycolysis and upregulating OXPHOS 
complex IV by the induction of the cytochrome c oxidase (COX) Cu2+ chaperone, SCO2. Because 
the inhibition of glycolysis can redirect glucose-6-phosphate into the pentose phosphate pathway, 
this could increase antioxidant defences in conjunction with increased OXPHOS. Thus, the 
inactivation of p53 should decrease OXPHOS in favour of glycolysis, increase ROS production and 
inhibit apoptosis (Wallace 2012). 
Moreover, the physical interaction of tumor suppressor with mtDNA, TFAM, POLG and the 
coactivator PGC-1α was reported (Yoshida 2003, Achanta 2005, Bakhanashvili 2008), overall, 
these data suggest a positive control of p53 on mitochondrial biogensis. Nevertheless, p53 has been 
recently called into play as negative regulator through its repressor activity at the promoters of 
murine homologues of the PGC-1β family in the context of telomere dysfunction (Sahin 2011). 
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2.2.2 p53 and DNA Damage Response  
 
 
At the end of the 1800 the German biologist Boveri suggested that the pathogenesis of 
cancer might be driven by a “specific and abnormal chromosome constitution”. A century later, 
genomic instability is recognized as a characteristic of most solid tumors and adult-onset 
leukaemias. In most cancers, the instability is obvious as alterations in chromosome number and 
structure, a phenotype termed chromosomal instability, and as changes to the structure of DNA, 
such as nucleotide substitutions, insertions and deletions. When they occur in crucial ‘driver’ genes 
these mutations can alter cell behavior, confer a selective advantage, drive the development of the 
disease and can also influence how the tumor will respond to therapy. Given the potentially 
devastating effects of genomic instability, cells have evolved an intricate series of interlocking 
mechanisms that maintain genomic integrity. The size of this task is daunting; the integrity of DNA 
is continually challenged by a variety of agents and processes that either alter the DNA sequence 
directly or cause mutation when DNA is suboptimal repaired (for example: ultraviolet component, 
ionizing radiation, cigarette smoke). The variety and frequency of DNA lesions are matched by the 
complexity of mechanisms that counteract these threats to genomic integrity. Collectively, these 
mechanisms are known as the DNA damage response (DDR) (Lord 2012). 
Nuclear DNA is undoubtedly the most precious component of a cell. It is not surprising therefore 
that any kind of damage that introduces a discontinuity in the DNA double helix elicits a prompt 
cellular reaction. The DNA damage response has two distinct, but coordinated, functions: it 
prevents or arrests the duplication and partitioning of damaged DNA into daughter cells to impede 
the propagation of corrupted genetic information and it coordinates cellular efforts to repair DNA 
damage and maintain genome integrity (d’Adda di Fagagna 2008). 
The DDR pathways consist of interconnected components that respond to DNA damage to allow 
repair and promote cell survival. The DNA repair pathways and downstream cellular responses 
have diverged in cancer cells compared with normal cells due to genetic alterations that underlie 
drug resistance, disabled repair and resistance to apoptosis. Consequently, abrogating DDR 
pathways represents an important mechanism for enhancing the therapeutic index of DNA-
damaging anticancer agents (Al-Ejeh2012). In cancer cells, an important a potential cause of DNA 
damage is represented also by replication stress that can be caused by oncogene-induced hyper-
replication that activates origins more than once per S phase, by nucleotide pool imbalance or by 
DNA damage; for example, by reactive oxygen species (Curtin 2012). 
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2.2.2.1 DDR signal transduction 
 
A wide range of DNA lesions elicit the activation of DDR pathways and subsequent cell 
cycle checkpoints. Genetic lesions include DNA base damage or base misincorporation, DNA 
crosslinks and DNA single strand breaks or double strands breaks. 
DDR pathways resemble the signaling paradigm established for growth factors, in which the 
cognate pathway comprises detection, signal transduction and effectors phases (Fig. 20). 
  
 
 
 
Fig. 20: DNA-damage response pathway. A set of targets lie downstream of ATM and ATR, including DNA repair 
proteins BRCA1, NBS1, BLM1, cAbl and 53BP1; cell cycle checkpoint proteins Chk1 and Chk2; and S-phase delay 
effectors FANCD2 and SMC1. In addition, downstream targets of ATM include p53 and MDM2, which are 
phosphorylated at Ser-15 and Ser-395, respectively. p53 is also phosphorylated by ATR at Ser-15. Furthermore, p53 is 
phosphorylated at Ser-20 by ATM-activated Chk2. Accumulation (by loss of MDM2 inhibition) and stabilization or 
activation of p53 (by phospho-Chk2 and phosphor-ATM-mediated phosphorylation) exert p53-dependent G1/S arrest or 
apoptosis.  
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The detectors of DNA-damage signaling activate signal transducers by recruiting them to sites of 
DNA damage and include the Mre11-Rad50-Nbs1 complex and replication protein A-coated single 
stranded DNA. The key signal transducers downstream of the detectors are the ataxia telangiectasia-
mutated (ATM) and ATM-Rad3-related (ATR) protein kinases. ATM and ATR are Ser/Thr-Gln-
directed protein kinases with overlapping substrate specificities. Whereas the ATM pathway is 
active during all phases of the cell cycle in response to double-strand breaks (DSBs), ATR acts 
primarily in S and G2 phases of the cell cycle in an ATM-dependent manner. The ATR pathway 
mainly responds to agents that interfere with the function of DNA replication forks (replication 
stress), such as ultraviolet light and gemcitabine, although it is now recognized that the ATR 
pathway can also activate downstream components of the ATM arm following replication fork 
stalling or ultraviolet treatment. In addition, DNA-alkylating agents can activate both pathways. 
Checkpoint proteins 1 and 2 (Chk1 and Chk2) are key downstream substrates of ATM and ATR. 
Chk1 or Chk2 phosphorylate several downstream substrates necessary for activating the DNA-
damage checkpoints and subsequently halting the cell cycle. More recently, the 
p38MAPK/MAPKAP-K2 (MK2) complex has been characterized as an additional checkpoint 
transducer downstream of ATM and ATR. The effectors lie downstream of signal-transducing 
molecules and are involved in the inhibition of cell cycle progression, DNA repair activation and 
maintenance of genome stability. When damage is beyond repair, proteins in the DDR network 
mediate one of two effectors functions: initiation of permanent cell cycle arrest (cellular 
senescence) or cell death. Characterizing these two outcomes will have important implications for 
understanding DDR signaling and improving the efficacy of DNA-damaging agents used in 
anticancer treatments. Although Chk1 and Chk2 proteins exhibit comparable cellular activities, 
Chk1 is important for checkpoint and replication arms of the DDR signaling, whereas Chk2 is more 
important for DNA-damage-induced apoptosis. However, as 50% of cancers lack functional p53, 
DDR signaling via the ATM/ATRChk2-p53 pathway is attenuated. Furthermore, while G1 arrest 
may be initiated independently of p53, it is not maintained owing to the lack of functional p53. 
Consequently, p53-mutant cancer cells are more resistant to apoptosis and rely on the S- and G2-
phase checkpoints to repair DNA damage and promote cell survival (Al-Ejeh 2012). 
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2.2.2.1.1 p53 as main effector of DDR 
 
 
The p53 signalling pathway is activated in response to a variety of stress signals, allowing 
p53 to coordinate transcription programmes that ultimately contribute to tumor suppression. Loss of 
p53 function, through mutations in p53 itself or perturbations in pathways signalling to p53, is a 
common feature in the majority of human cancers. More than 75% of the mutations result in the 
expression of a p53 protein that has (in most cases) lost wild-type functions and may exert a 
dominant-negative regulation over any remaining wild-type p53. Most interestingly, however, 
mutant p53 also acquires oncogenic functions that are entirely independent of wild-type p53 
(Muller 2013).  
In normal unstressed cells, p53 is a very unstable protein with a half-life ranging from 5 to 30 min, 
which is present at very low cellular levels owing to continuous degradation largely mediated by 
MDM2. Principally, MDM2 is an E3 ligase and promotes p53 degradation through a ubiquitin-
dependent pathway on nuclear and cytoplasmic 26S proteasomes. Importantly, MDM2 itself is the 
product of a p53. Thus, the two molecules are linked to each other through an autoregulatory 
negative feedback loop aimed at maintaining low cellular p53 levels in the absence of stress (Fig. 
21) (Moll 2003) 
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Fig. 21: Regulation of p53 by MDM2. p53 and MDM2 form an autoregulatory feedback loop. p53 stimulates the 
expression of MDM2; MDM2, in turn, inhibits p53 activity because it stimulates its degradation in the nucleus and the 
cytoplasm, blocks its transcriptional activity, and promotes its nuclear export. A broad range of DNA damaging agents 
or deregulated oncogenes induces p53 activation. DNA damage promotes phosphorylation of p53 and MDM2, thereby 
preventing their interaction and stabilizing p53. Likewise, activated oncogenes induce ARF protein, which sequesters 
MDM2 into the nucleolus, thus preventing the degradation of p53. Conversely, survival signals mediate nuclear import 
of MDM2 via Akt activation, which destabilizes p53 (Moll 2003). 
 
There are multiple layers of regulation that connect MDM2 function with p53 stability during stress 
responses. A prominent physiological regulator of MDM2 is the tumor suppressor ARF. ARF 
interferes with the MDM2-p53 interaction, thereby acting to stabilize and activate p53. The low 
steady-state levels of ARF in normal cells are dramatically induced upon oncogenic stress. 
Interestingly, although the level of p53 is elevated in the absence of MDM2, p53 is still degraded in 
the cells of MDM2 null mice, suggesting the existence of alternative, MDM2-independent pathways 
for p53 degradation in vivo. Indeed, the recently discovered E3-ligases COP1, Pirh2, Arf-BP1, and 
others have clearly been shown to contribute to the efficient control of p53 levels in tissue culture 
and in vitro biochemical experiments. Nevertheless, the precise roles of MDM2-independent 
degradation in stress-induced p53 stabilization remain to be elucidated (Kruse 2009).  
Phosphorylation of p53 is classically regarded as the first crucial step of p53 stabilization. p53 can 
be modified by phosphorylation by a broad range of kinases, including ATM/ATR/DNAPK, and 
Chk1/Chk2. Phosphorylation of serine residues within the N-terminal p53 transactivation domain 
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was among the first posttranslational modifications of p53 identified and has been extensively 
investigated in vitro biochemical assays, in tissue culture studies, and recently by using sitespecific 
knockin animals. N-terminal phosphorylation at Ser15 (mouse Ser18) and Ser20 (mouse Ser23) 
have been generally thought to stabilize p53 by inhibiting the interaction between p53 and MDM2 
(Fig. 22). Ser15 and Ser20 are phosphorylated after DNA damage and other types of stress by 
ATM, ATR, DNA-PK, Chk1, and Chk2 Although it remains unresolved which of the different 
kinases perform the phosphorylation of these N-terminal regulatory sites in response to the varying 
stress signals, and to which extent N-terminal phosphorylation affects the p53-MDM2 interaction, 
the general consensus remains that their phosphorylation occurs rapidly in response to various stress 
stimuli to activate p53 (Kruze 2009). 
 
 
 
Fig. 22: Classical Model of p53 Activation. The classical model for p53 activation generally consists of three 
sequential activating steps: (1) stress-induced stabilization mediated by phosphorylation (P), (2) DNA binding, and (3) 
recruitment of the general transcriptional machinery. During normal homeostasis, p53 is degraded after Mdm2-
mediated ubiquitination (left), while stress signal-induced p53 phosphorylation by ATM, ATR, and other kinases 
stabilizes p53 and promotes DNA binding. DNA-bound p53 then recruits the transcriptional machinery to activate 
transcription of p53 target genes (Kruse 2009). 
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Once stabilized, p53 exerts tumor-suppressive functions by inducing the expression of effectors 
genes by interaction with specific DNA sequence within the promoter regions of target genes and 
through posttranslational modification like acetylation.  
As a transcription factor, p53 recognizes its target genes by binding to a consensus response 
element located proximal to the transcription start site either at the gene promoter, the first intron or 
even further downstream of the gene. The canonical p53 consensus response element (p53RE) was 
originally defined as two tandem copies of a decamer motif “RRRCWWGYYY” separated by a 0–
13 bp spacer, where “R” represents purines, “W” represents adenine or thymine, and “Y” represents 
pyrimidines. The initial description of the decamer half-site with a “CWWG” core as 
“C(A/T)(T/A)G” greatly facilitated the identification of many p53 target genes. Conversely, mutant 
p53 derived from tumors failed to bind to the canonical p53RE, leading to a loss of function that is 
characteristic of a tumor suppressor (Wang 2010).  
Histone acetyltransferases (HATs) provide an important layer of p53 regulation, particularly in 
transcription. p53 is acetylated by the histone acetyltransferase CBP/p300, and CBP/p300 mutations 
are found in several types of human tumors. The acetylation is critically important both for the 
efficient recruitment of cofactors and for the activation of p53 target genes in vivo. Once localized 
at promoter regions, CBP/p300 can enhance transcription by acetylating histones in the vicinity of 
target genes, thereby establishing a more accessible chromatin conformation, and by bridging 
transcription factors to the pol II holoenzyme (Kruse 2009).  
Two large subsets of p53 target genes have been identified: (I) negative regulators of cell cycle 
progression, such as the p21 cyclin-dependent kinase inhibitor 1A (CDKN1A), 14-3-3σ, and growth 
arrest and DNA damage-inducible gene (GADD45α); and (II) apoptosis-promoting genes, such as 
p53 upregulated modulator of apoptosis (PUMA) as well as the BH domain proteins Bcl-2-
associated protein X (BAX) and Bcl-2 antagonist/killer (BAK). Mutational inactivation of p53 
allows the uncontrolled proliferation of damaged cells. By contrast, the expression of dominant 
active forms of p53, leading to constitutive expression of downstream genes, results in degenerative 
phenotypes and premature aging (Reinhardt 2012) (Fig. 23).  
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.  
Fig. 23: p53 Acetylation and Target Gene Regulation. Upon stress-induced p53 activation, different sets of p53 
target genes have different requirements for p53 posttranslational modifications. (A) A number of promoters can be 
activated by unacetylated p53. This class of p53 target genes protects cells from excessive p53 activation. These target 
genes include Mdm2, Pirh2, and others. (B) The activation of genes involved in DNA repair and cell cycle control 
requires recruitment of specific histone acetyltransferases (HATs) and partial acetylation (Ac), acting at least in part by 
antirepression. (C) Full acetylation of p53 is required for the activation of proapoptotic genes. Activation of these 
targets induces a program to ensure efficient apoptosis (Kruse 2009). 
 
 
2.2.2.2  Cellular senescence as DNA damage response 
 
The impact of DDR activation may be different: if the DNA damage that is generated in 
proliferating cells is promptly and properly fixed, cells will quickly resume normal proliferation. By 
contrast, when DNA damage is particularly severe, cells may undergo programmed cell death 
(apoptosis), a cellular form of suicide that removes damaged cells from a cell population. However, 
an additional outcome is also possible: cells may initiate cellular senescence, a naturally irreversible 
cell-cycle arrest that is induced by DDR signalling. It is still unclear what determines the choice 
between apoptosis and senescence, but determinants may include cell type and the intensity, 
duration and nature of the damage. In contrast to quiescence, senescence cannot be reversed by 
altering the cellular environment, by removing cell contact inhibition or providing abundant 
nutriments in vitro.(d’Adda di Fagagna 2008).   
The first description of ‘cellular senescence’ dates to 1965 when Leonard Hayflick observed that 
cells undergo a replicative senescence in culture. It is now well established that premature forms of 
cellular senescence can be triggered by DNA damage agents, and through either the activation of 
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oncogenes (a type of senescence that is termed oncogene-induced senescence (OIS) or the loss of 
tumour suppressor genes, including PTEN, RB1, NF1 and INPP4B (Fig. 24) (Nardella 2011). 
 
 
 
Fig. 24: Differential senescence responses. Several independent stimuli have the capacity to induce senescence 
through various common effectors. These differential stimuli can be categorized as replicative senescence, oncogene-
induced senescence (OIS) and PTEN loss-induced cellular senescence (PICS). Upstream effectors are shown in dark 
blue, DNA damage transducers in red and downstream effectors in yellow. a Replicative senescence is driven by 
multiple stimuli, including telomere erosion, and can result in activation of INK4A (also known as p16) expression and 
can trigger DNA damage pathways resulting in p53 induction. b In OIS, the activation of p53 is driven by two main 
mechanisms. First, it is stabilized through phosphorylation by the DNA damage response (DDR) and second, by ARF-
mediated stabilization.. c By contrast, p53 upregulation in PICS is mainly mediated through translational mechanisms 
that are controlled by mTOR. In addition, the ETS2–INK4A pathway is also required for senescence induction. 
Although RAS–MAPK signalling directly promotes ETS2 activity34, PICS-mediated activation of ETS2 occurs 
through the deregulation of ETS2 degradation by the CDH1-containing anaphase-promoting complex (APC/C (also 
known as the cyclosome)–CDH1). d Senescence induction can also be achieved through targeting key inhibitors of 
senescence. For example, MYC inactivation can result in the restoration of transforming growth factor-β (TGFβ) 
signalling pathways resulting in senescence, and the inhibition of S phase kinase-associated protein 2 (SKP2) in 
combination with additional oncogenic events (Nardella 2011). 
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Despite the different modes of activation, all senescent cells present common features. Senescent 
cells differ from other nondividing (quiescent, terminally differentiated) cells in several ways, 
although no single feature of the senescent phenotype is exclusively specific. Hallmarks of 
senescent cells include (Rodier 2011) (Fig. 24):  
(I) The senescence growth arrest is permanent and cannot be reversed by known physiological 
stimuli.  
(II) Senescent cells increase in size, sometimes enlarging more than twofold relative to the size of 
nonsenescent counterparts (Hayflick 1965). 
(III) Senescent cells express a senescence-associated β-galactosidase (SA-β-gal) (Dimri 1995), 
which partly reflects the increase in lysosomal mass 
(IV) Most senescent cells express p16INK4a, which is not commonly expressed by quiescent or 
terminally differentiated cells. In some cells, p16INK4a, by activating the pRB tumor suppressor, 
causes formation of senescence-associated heterochromatin foci (SAHF), which silence critical pro-
proliferative genes. p16INK4a, a tumor suppressor, is induced by culture stress and as a late 
response to telomeric or intrachromosomal DNA damage. Moreover, p16INK4a expression 
increases with age in mice and humans and its activity has been functionally linked to the reduction 
in progenitor cell number that occurs in multiple tissues during aging.  
(V) Cells that senesce with persistent DDR signaling harbor persistent nuclear foci, termed DNA 
segments with chromatin alterations reinforcing senescence (DNA-SCARS). These foci contain 
activated DDR proteins, including phospho-ATM and phosphorylated ATM/ataxia telangiectasia 
and Rad3 related (ATR) substrates, and are distinguishable from transient damage foci. DNA-
SCARS include dysfunctional telomeres or telomere dysfunction–induced foci. 
(VI) Senescent cells with persistent DDR signaling secrete growth factors, proteases, cytokines, and 
other factors that have potent autocrine and paracrine activities.  
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Fig. 24: Hallmarks of senescent cells. Senescent cells differ from other nondividing (quiescent, terminally 
differentiated) cells in several ways, although no single feature of the senescent phenotype is exclusively specific. 
Hallmarks of senescent cells include an essentially irreversible growth arrest; expression of SA-Bgal and p16INK4a; 
robust secretion of numerous growth factors, cytokines, proteases, and other proteins (SASP); and nuclear foci 
containing DDR proteins (DNA-SCARS/TIF) or heterochromatin (SAHF). The pink circles in the nonsenescent cell 
(left) and senescent cell (right) represent the nucleus. 
 
Studies of human tissues and cancer-prone mice argue strongly that cellular senescence suppresses 
cancer in vivo. Premalignant human nevi and colon adenomas contained cells that express 
senescence markers, including SA-β-gal and DDR signaling; however, senescent cells were 
markedly diminished in the malignant melanomas and adenocarcinomas that develop from these 
lesions. Likewise, in mouse models of oncogenic Ras expression or Pten deletion, senescent cells 
were abundant in premalignant lesions, but scarce in the cancers that eventually developed. Further, 
dismantling the senescence response by inactivating p53 caused a striking acceleration in the 
development of malignant tumors (Rodier 2011). The concept of pro-senescence therapy has 
emerged over the past few years as a novel therapeutic approach to treat cancers. However, unlike 
the field of apoptosis, which was embraced with great fervor in its promise to cure cancer by cell 
suicide, there has been little excitement surrounding the use of senescence as a cancer therapy 
strategy. This scepticism mostly arose from the prevailing dogma that senescent cells were not 
cleared by the immune system, but remained part of the tissue. (Nardella 2011). Second, senescent 
cells develop a secretory phenotype (SASP) that can affect the behavior of neighboring cells. 
Strikingly, many SASP factors are known to stimulate phenotypes associated with aggressive 
cancer cells. For example, senescent fibroblasts secrete amphiregulin and growth-related oncogene 
(GRO) α, which, in cell culture models, stimulate the proliferation of premalignant epithelial cells. 
Senescent cells also secrete high levels of interleukin 6 (IL-6) and IL-8, which can stimulate 
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premalignant and weakly malignant epithelial cells to invade a basement membrane. Further, 
senescent fibroblasts and mesothelial cells secrete VEGF, which stimulates endothelial cell 
migration and invasion (a critical step in tumor-initiated angiogenesis), and senescent fibroblasts 
and keratinocytes secrete matrix metalloproteinases (Rodier 2011). Hence, cancer cells in a 
senescent state might remain as ‘dormant’ malignant cells, and therefore represent a dangerous 
potential for tumor relapses, since through disruption of p53 and p21 function they may escape 
senescence (Brown 1997, Beausejour 2003).  
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3. AIMS of the STUDY 
 
Radiotherapy (RT) is one of the most effective non-surgical treatments of cancer patients 
with better functional preservation and less systemic influences. Cellular response to γ-rays is 
mediated by Ataxia telangiectasia mutated (ATM) kinase and the downstream effector p53. When 
p53 is phosphorylated, it can transactivate several genes to induce permanent cell cycle arrest 
(senescence) or apoptosis. Epithelial and mesenchymal cells as well as their derived tumor cells are 
more resistant to radiation-induced apoptosis and respond mainly by activating senescence. Hence, 
tumor cells in a senescent state might remain as “dormant” malignant cell in fact through disruption 
of p53 function, cells may overcome growth arrest. A particular type of relapses after γ-rays was 
observed in patients with colorectal cancer, where oncocytic features were acquired in the recurring 
neoplasia after radiation therapy. Oncocytic tumors are characterized by aberrant biogenesis of 
nonfunctional mitochondria in their cells. They are mainly non-aggressive neoplasms and their low 
proliferation degree can be explained by chronic destabilization of HIF1α, which presides to 
adaptation to hypoxia and mediates the progression of cancer cells towards malignancy. Moreover, 
it also plays a pivotal role in hypoxia-related tumor radio-resistance since it is able to interfere with 
the signalling of p53, and hence to block the senescent program induced by γ-rays. The aim of this 
project was to verify whether mitochondrial biogenesis can be induced following radiation 
treatment, in relation of HIF1α status, and whether such a mechanism is predictive of a senescence 
response. To this purpose, in vitro and in vivo studies have been designed, in order to assess:  
1. the molecular mechanisms involved in mitochondrial biogenesis due to radiation treatment; 
2. whether p53 is a key regulator of mitochondrial biogenesis; 
3. the role of HIF1α in regulating mitochondrial biogenesis and senescence induced by γ-rays; 
4. whether mitochondrial biogenesis parameters could be utilized as prognostic markers to predict 
the stabilization of HIF1α after radiation treatment. 
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4. MATERIALS AND METHODS 
 
4.1 Cell cultures 
 
Human colorectal carcinoma cell line HCT116, their genetically modified derivates lacking 
TP53 (Bunz 1998), HCT116
TP53-/-, and the osteosarcoma cell line HPS11 were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 
100units/mL penicillin, 100μg/mL G-streptomycin and 2mmol/L L-glutamine. RPE1 (non-tumor 
human retinal ephitelial cell line) were cultured in DF12 medium [DMEM/nutrient mixture F-12 
ham (Sigma-Aldrich)] supplemented with 10% FBS and 100units/mL penicillin, 100μg/mL G-
streptomycin. Cell lines were maintained in a humidified incubator at 37 °C with 5% CO2. 
 
4.2 γ-rays treatment and HIF1α compound-mediated stabilization 
 
Treatment was optimized to (I) use γ-rays doses close to those currently used in 
radiotherapy, (II) maintain cells viable and (III) eliminate dead cells from the population. 200.000 
cells were seeded per 25cm2 flask (T0). The following day flasks were submitted to a dose of 4 
Gray (Gy), specifically 2 Gy/min with the biological irradiator IBL437C (89-294). The treatment 
was repeated after exactly 24 hours for 4 days (IR). Alternatively, cells were allowed to recovery 
for 120 hours before harvesting (REC). The medium was changed after the last dose of irradiation. 
HIF1α was stabilized by adding the inhibitor of proline hydroxylase dimethyloxallylglycine 
(DMOG, 1μM) or the iron chelator desferrioxamine (DFO, 250nM) (Sigma-Aldrich) to the culture 
medium for the entire duration of the radiation treatment. 
 
4.3 Western blotting 
 
Proteins were extracted from snap-frozen tissue using RIPA Lysis Buffer [TrisHCl (50mM), 
NaCl (150mM), SDS (0.1%), Triton (1%), EDTA (1mM, pH 7.6)]. Total lysates (80g) were 
denaturated for 5min at 99°C in Laemli Buffer [SDS (4%), beta-Mercaptoethanol (10%), Glicerol 
(20%), Tris (125mM, pH 6.8), bromo-phenol-blue (0.25%)] and separated by SDS–PAGE (10%). 
Hybond-ECL nitrocellulose membranes (GE Healthcare) were incubated with antibody against 
beta-actin (1:20000, Sigma), HIF1alpha (1:1000, Bethyl Laboratories, Montgomery, TX, USA) γ-
tubulin (Sigma), p53, p21, p16  (Santa Cruz biotechnologies), OPA1 (Bioscience), TFAM 
(AbCam), SDHA, SDHB, NDUFA9, NDUFS3 (MitoSciences), ATP5β (BioVision), VDAC 
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(Millipore), Core II (Invitrogen) and MDM2 (Calbiochem). Western Breeze Kit (Invitrogen) was 
used for blocking, secondary antibody and chemilumenescent substrate incubations. 
 
4.4 Nucleic acid extraction and reverse transcription 
 
DNA from cell lines and snap-frozen mouse tumors was extracted using QIAamp DNA 
Mini Kit (Qiagen, Hilden, Germany). RNA extraction was performed using the Trizol reagent 
(Invitrogen) according to the manifacturer protocol. Cells are first pelleted at 1500 rpm for 5’, then 
the pellet are washed twice in PBS buffer. The pellet is suspended in 300 μL of Trizol Reagent and 
transfered in a new tube.Follows an incubation a RT for 5’. 60 μL of chloroform are added to 
separated the two phases. The tube is shaker 15” in hands and then incubated at RT for 2-3’. Then 
the tube is centrifugated at 12.000g for 15’ at 4°C. The aqueous phase is removed avoid drawing 
any of the interphase or organic layer, and transferred to a new tube and the RNA isolation phase 
begins. 200 μL of isopropanol is added and the mix is incubated 10’ at RT. Then is centrifugated at 
1200g for 10’ at 4°C. The supernatant is removed to leave only the pellet in the tube. The pellet is 
washed by adding 200μL of ethanol (70%) and centrifugated at 7500g at 5’. Finally the ethanol is 
removed and the pellet is air dried and resuspended in 20-40 μL of RNAase-free water and 
incubated for 10’ at 55°C-60°C to help resuspension. The integrity of the RNA is verified on 
electrophoresis gel at 1%. For the quantification is utilized the Nanodrop (Thermo Scientific). 
cDNA was prepared by retrotranscription of 1µg of total RNA with High Capacity cDNA Reverse 
Transcription Kit (Life Technologies). 
 
4.5 MtDNA sequencing 
 
Whole mtDNA resequencing was performed with MitoAll (Applied Biosystems) as 
previously described (Bonora 2006). Electropherograms were analyzed with Sequencing Analysis 
version 2.5.1 software and inspected with SeqScape version 2.5 software (Applied Biosystems). 
Sequencing was performed with Big Dye v3.1 (Applied Biosystems, Foster City, CA, USA) in 10µl 
final volume, according to the manufacturer’s instructions and run on a 3730 DNA Analyzer 
(Applied Biosystems).  
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4.6 mtDNA copy number 
 
Mitochondrial DNA content was evaluated by a Real Time-PCR multiplex assay based on 
hydrolysis probe chemistry. Briefly, a mtDNA fragment (MTND2 gene) and a nuclear DNA 
fragment (FASLG gene) were co-amplified in the same PCR reaction. The concentration of mtDNA 
normalized on nuclear DNA in the samples was extrapolated from a standard curve of serial 
dilution of a vector in which the templates  for the two amplifications were cloned tail to tail, to 
have a ratio of 1:1. Primers, probe and conditions were previously published (Cossarizza 2003). 
About 2ng of DNA extracted from cells and tissues were analysed using the LightCycler® 480 
Probes Master Mix (Roche) and  the LightCycler® 480 (Roche) instrument.  
 
4.7 Gene expression analyses via Real-Time PCR 
 
Quantitative Real-time PCR (qRT-PCR) for MT-ND5, p21, GADD45α, BAX, PGC-1β, 
HIF1α, and TUBB1 was performed on cDNA diluted 1:50. The qRT-PCR reaction was performed 
with GoTaq® qPCR Master Mix (Promega) and run in 7500 Fast Real-Time PCR System (Life 
Technologies), using following conditions: 95°C 5min; 45 cycles of 95°C 15sec and 60°C 45sec. 
The calculations were performed following 2
-ΔΔCT
 method. Primer sequences were designed using 
Primer3 software (Rozen 2000). Primer sequences are listed in Appendix A.  
 
4.8 Cellular and mitochondrial morphology 
 
Cellular and mitochondrial morphology was assessed after cell staining with 100nM calcein- 
acetoxymethyl ester (calcein-AM, Life Technologies) and 10nM MitoTracker Red (MTR - Life 
Technologies) for 30min at 37°C. Images were acquired with a digital imaging system using an 
inverted epifluorescence microscope with 63X/1.4 oil objective (Diaphot, Nikon, Japan) and a 
back-illuminated Photometrics Cascade CCD camera system (Roper Scientific, Tucson, AZ, USA). 
Images were captured and analyzed using the Metamorph software (Universal Imaging Corp., 
Downingtown, USA). 
 
4.9  ATP synthesis evaluation 
 
The amount of cellular ATP was determined by using the luciferin/luciferase assay as 
previously described (Zanna 2005). The measurements of mitochondrial ATP synthesis were done 
in cells grown in DMEM‐glucose according to Manfredi (Manfredi 2002), with minor 
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modifications. Briefly, after trypsinization, cells were resuspended (7x106/ml) in buffer A [KCl 
(10mmol/L), Tris‐HCl (25mmol/L), EDTA (2mmol/L), bovine serum albumin (0.1%), potassium 
phosphate (10mmol/L), MgCl2 (0.1mmol/L, pH 7.4)], kept for 15min at room temperature, and 
then incubated with 50 μg/mL digitonin for 1min. After centrifugation, the cells pellet was 
resuspended in buffer A and aliquots were taken to measure ATP synthesis, protein content 
(Bradford 1976), and citrate synthase activity (Trounce 1996). Cell aliquots were incubated with 
Complex I substrates malate (5mmol/L) plus glutamate (5mmol/L) in the presence or absence of 
oligomycin (10μg/mL), or with the Complex II substrate succinate (10mmol/L) plus rotenone 
(2μg/mL), and ADP (0.2mmol/L) for 1 and 3min. The amount of ATP was measured as described 
140. The rate of ATP synthesis was expressed as a ratio of citrate synthase activity (Trounce 1996). 
Dichlorodihydrofluorescein diacetate was obtained from Molecular Probes (Invitrogen) and ATP 
monitoring kit from BioOrbit (Turku, Finland). 
 
4.10 In silico promoter analyses 
The promoter and 5’UTR regulatory regions of the PGC-1β gene were scanned to verify the 
presence of one or more p53 responsive elements (p53REs) using the PatSearch algorithm 
implemented in the DNAfan tool (Gisel 2004, Grillo 2003). The syntax pattern of the p53RE is 
made up of two tandem repeated decamers complying with a specific consensus corresponding to 
the 5’-PuPuPuC(A/T)(T/A)GPyPyPy-3’ sequence, allowing at most 3 mismatches. The decamers 
can be spaced by 0 to 13 nt. The in silico analysis revealed the presence of one p53RE at position -
2732; -2706 (promoter region) upstream the Transcription Start Site (TSS) of the PGC-1β gene 
(GRCh37 - Entrez Gene ID:133522).  
4.11 Chromatine immunoprecipitation  
 
After treatments, proteins were cross-linked to DNA in living nuclei by adding 
formaldehyde directly to the cell culture medium to a final concentration of 1%. Cross-linking was 
allowed to proceed for 10 min at 37°C. Cross-linked cells were washed with phosphate-buffered 
saline, scraped off the plates and resuspended in 20mM Tris-chloride pH=8.3, 3mM MgCl2, 20 mM 
KCl, 1mM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin. Nuclei were 
pelleted by microcentrifugation and lysed by incubation in nuclear lysis buffer (1% sodium dodecyl 
sulphate, 10mM EDTA, 50mM Tris-chloride pH=8.1, 1mM phenylmethylsulfonyl fluoride, 1μg/ml 
leupeptin, 1μg/ml aprotinin). The resulting chromatin solution was sonicated in order to generate 
300-1000bp DNA fragments. After microcentrifugation, the supernatant was diluted with dilution 
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buffer (0.01% sodium dodecyl sulphate, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-chloride 
pH=8.1, 167mM NaCl, 1mM phenylmethylsulfonyl fluoride, 1μg/ml leupeptin, 1μg/ml aprotinin) 
and precleared with protein A-Agarose/salmon sperm DNA and divided into aliquots. Five 
micrograms of p53 and HIF1α antibodies (Santa Cruz) or any antibody (as negative control), was 
added to the chromatin solution and incubated on a rotating platform O.N. at 4°C. In parallel, we 
added acetylated H4-histone antibody (Upstate
TM
) or any antibody (as negative control) to a small 
fraction of the chromatin solution. Antibody-protein-DNA complexes were precipitated with 
protein A-Agarose/salmon sperm DNA. After centrifugation, the beads were washed and the 
protein-DNA complexes were eluted with 1% sodium dodecylsulphate, 100 mM Sodium 
Carbonate. DNA-protein cross-links were reversed by heating at 65°C for 4 hours and DNA was 
phenol extracted and ethanol precipitated. DNA fragments were analyzed by Real Time q-PCR 
using SybrGreen and primers specific for the CDKN1A (p21), as p53 activation-positive control, 
and PGC-1β.  
 
4.12 P53 PCR amplification and sequencing  
 
All 10 coding exons of TP53 and exon-intron boundaries of the gene were amplified using 
Fast Start Taq DNA Polymerase (Roche). PCR amplification was performed in a final volume of 
25µl in a 9700 thermal cycler (Life Technologies), and PCR products were purified with 
Multiscreen PCR clean-up Filter Plates (Millipore). Primer sequences are listed in Appendix A. 
Sequencing was performed with BigDye v1.1 (Life Technologies) on both strands according to the 
manufacturer’s instructions. Briefly, 0.32µM of primer were used in 10µl final reaction, together 
with 0.5µl of BigDyev1.1 and 2µl of Buffer (2x). Upon cycling (4 minute elongation) the amplicons 
were precipitated and run in a ABI3730 Genetic Analyzer automated sequencing machine (Life 
Technologies). Electropherograms were analyzed using Chromas Lite v.2.01 (Technelysium).  
 
4.13 TP53, MDM2, HIF1α and HIF1αTM cloning 
 
Plasmid for overexpression of p53 was previously done. The full length cDNA of MDM2 
and HIF1α was amplified by total cDNA obtain from RNA of RPE1 cells using the follow primer: 
Bst1107I_Mdm2_fw: TGCGTATACCCACCATGGTGAGGAGCA 
BamHI_Mdm2_rv: ACGGATCCCTAGGGGAAATAAGTTA 
BspeI_ HIF1_fw: CGTCCGGAGCCACCATGGAGGGCG 
BamHI_HIF1_rv: GACGGATCCTAGTTAACTGATCCAAAG 
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The PCR product is first cloned in pGEM-T Easy vector system (Promega) for the amplification. 
DH5α competent cells were transformed with the plasmid: pGEM_HIF1 or pGEM_MDM2 and 
selected on Luria-Bertani medium containing ampicillin (100µg/mL) and 5-bromo-4-chloro-3-
indolyl-h-D-galactopyranoside (3%). White colonies were picked and grown at 37°C in Luria-
Bertani medium/ ampicillin (100µg/mL). DNA was extracted using in-house suspension [Tris 
(15mM, pH 8.0), EDTA (10mM), RNaseA (100µg/ml)], lysis [NaOH (0.2M), SDS (1%)] and 
neutralization [KAc (3M, pH 5.5)] buffers and the presence of the insert was verify using Sanger 
sequencing. The full length cDNA of HIF1α and MDM2 present in pGEM_HIF1 and 
pGEM_MDM2 was inserted in pcDNA3.1 vector (Invitrogen) after digestion with restriction 
enzyme (Bst1107I and BamHI for MDM2; BspeI and BamHI for HIF1α). The complete sequence 
of these plasmids was verified using Sanger sequencing. 
To generate a form of HIF1α that is not subjected to proline hydroxylase degradation, HIF1αTM, 
aminoacids P402, P564 and P803 of HIF1α were replaced with alanine residues. In normoxic 
conditions, O2-dependent hydroxylation of proline (P) residues 402 and 564 in HIF1α by the 
enzymes PHD (prolyl hydroxylase-domain protein) 1–3 is required for the binding of the von 
Hippel–Lindau (VHL) and next degradation. O2 also regulates the interaction of HIF-1α with 
transcriptional co-activators. O2-dependent hydroxylation of asparagine (N) residue 803 in HIF1α 
by the enzyme FIH-1 (factor inhibiting HIF-1) blocks the binding of p300 and CBP to HIF-1α and 
therefore inhibits HIF-1-mediated gene transcription. Under hypoxic conditions, the rate of 
asparagine and proline hydroxylation decreases. VHL cannot bind to HIF-1α that is not prolyl-
hydroxylated, resulting in a decreased rate of HIF-1α degradation. By contrast, p300 and CBP can 
bind to HIF1α that is not asparaginyl-hydroxylated, allowing transcriptional activation of HIF-1 
target genes (Fig. 25) (Semenza 2003).  
 
Fig. 25 O2 –dependent regulation of HIF1α activity. The residue underline in red are those that was replaced with 
alanine residues (Semenza 2003).  
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Aminoacids P402, P564 and P803 of HIF1α were replaced with alanine using QuikChange Site-
Directed Mutagenesis Kits (Agilent) with the following primers: 
 
P402A5'-ACTTTGCTGGCCGCAGCCGCTGGAG-3'  
P402A_antisense5'-CTCCAGCGGCTGCGCCACAAAGT-3'  
P564A5'-TAGACTTGGAGATGTTAGCTATATCCCAATGGATGATG-3'  
P564A_antisense5'-CATCATCCATTGGGTATAGCTAACATCTCCAAGTATA-3'  
N803A5'-CACAGCTGACCAGTTATGATTGTGAATTGCTGCTCCTATACAAGG-3'  
N803A_antisense5'-CCTTGTATAGGAGCAGCAACTTCACAATCATAACTGGTCAGCTGT-3' 
 
The stabilization of HIF1αTM in presence of oxygen was verified through western blot analysis 
performed on HCT116 cells trasfected with the plasmid pcDNA3.1_HIF1αTM (Fig. 26).  
 
 
Fig. 26: Western blot analysis of HCT116 cells trasfetceted with pcDNA_HIF1TM. Cells treated with DFO were used 
as positive controls for the stabilization of HIF1α. 
 
 
 
4.14 Cells transfection  
 
Cells were seeded the day before in concentration that allow to reach the 70-90% of 
confluence in 24 h. The transfection reaction was performed using the X-treme GENE HP DNA 
Transfction Reagent (Roche), following the manufacturer protocol. At 600μl of serum free medium; 
6 μg of vector and 18μl of transfection reagent were added. This mix was added in the medium of 
the cells. The cells were incubated at 37°C for 48h and then utilized for the following experiments.  
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4.15 HIF1α degradation evaluation 
 
For protein stability analysis, the cells were treated with 10 μM cycloheximide, an inhibitor 
of protein biosynthesis in eukaryotic organisms, and then whole cell lysates were prepared after 
different time of incubation. The lysates (30 μg) were then subjected to Western blot analysis to 
identify the HIF1α. Treatments with cycloheximide (50μg/ml) were performed at 24h after MDM2 
transfection and cells collected after 0, 10 and 20 minutes of incubation. 
 
 
4.16 Senescence-associated β-galactosidase assay  
 
Increased β-Gal activity was determined following a protocol previously described (). The 
assay was performed on irradiated cells after recovery. Cells were washed twice with PBS and then 
incubated for 7 min with a fixation solution (2% formaldehyde and 0.2% glutaraldehyde in PBS). 
Cells were washed five times with PBS and incubated with a staining solution (40mM citric acid/Na 
phosphate buffer pH6, 1mg/ml X-gal, 5mM K4[Fe(CN)6]3H2O, 5mM K3[Fe(CN)6], 150mM NaCl 
and 1mM MgCl2 in ddH20) at 37°C until β-Gal staining became visible. Cells were finally washed 
five times with PBS. 
 
4.17 Rectal biopsies collection 
 
The study included 32 male patients, 18 years of age and older with prostate cancer. All 
patients underwent three-dimensional conformal radiotherapy and, by using 4-5-field techniques, a 
minimum energy of 6 MV was applied on linear accelerators. A computed tomography scan was 
performed before radiotherapy in order to enhance the reliability of the rectal dose-volume 
histogram. Dosing schedules followed the institutional protocols. During the treatment, patients laid 
in the supine position and were immobilised at the pelvis. Over 6-7 weeks period, using daily 
fractionation of 2Gy for 5 days a week, patients received a total dose of external-beam radiation 
ranging from 66 to 74Gy, given in 33-37 fractions. The radiation dose was prescribed to the 
isocentre (Fuccio 2011). During the examination by rectosigmoidoscopy, bioptic sampling was 
performed from the anterior wall of the rectum, 10cm above the anal verge, prior to and one month 
after the radiotherapy. Samples were snap frozen and kept at -80°C until the molecular analysis was 
performed. Patients were enrolled following internal ethical committee procedures. 
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5. RESULTS 
 
5.1 Effect of γ-rays on mitochondrial biogenesis 
 
Radiotherapy (RT) is one of the most effective non-surgical treatments of cancer patients 
with better functional preservation and less systemic influences. Tumor cells may escape the lethal 
effects of radiation and result in disease relapse (Kim 2005). Cellular response to γ-rays is mediated 
by ATM and the downstream effector p53. When p53 is phosphorylated, it can transactivate several 
genes to induce permanent cell cycle arrest (senescence) or apoptosis (Kruse 2009). A particular 
type of relapses after γ-rays was observed in patients with colorectal cancer, where oncocytic 
features were acquired in the recurring neoplasia after radiation therapy (Rouzbahman 2006, 
Ambrosini-Spaltro 2006). It has been demonstrated that genotoxic stress induced by γ-radiation 
increase mtDNA copy number, an index of mitochondrial biogenesis, in spleen and brain of total-
body irradiated mouse (Malakhova 2005). 
In order to test the effect of γ-rays commonly used in radiotherapy on mitochondrial biogenesis, a 
radiation treatment were optimized in order to: (i) use γ-rays doses close to those currently used in 
radiotherapy, (ii) maintain cells viable, (iii) eliminate dead cells from the population.  
Different cell lines were submitted to a dose of 4 Gray (Gy) every 24 hours for 4 days (IR).  
Alternatively, cells were allowed to recovery for 120 hours before harvesting (REC). 
The first experiments were conducted on TP53 wild type cell lines, namely non-tumor immortalized 
retinal epithelial, RPE1, to understand what is the response of non-tumor cell to γ-rays in term of 
mitochondrial biogenesis and colorectal tumor-derived cancer cell line, HCT116, since oncocytic 
relapses have been observed in rectal tissues. 
Both cell lines survived to radiation treatment and were able to proliferate until the recovery (Fig. 
27), and the significant increase upon irradiation of p53 demonstrated the activation of genotoxic 
response, (Pandita 2000). It was further confirmed by increased expression of p53 target gene p21, a 
cyclin-dependent kinase inhibitor that plays essential roles in the DNA damage response by 
inducing cell cycle arrest and direct inhibition of DNA replication (Jung 2010) (Fig. 28).  
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Fig. 27 Cells viability of RPE1 (A) and HCT116 (B) cell during radiation treatment at the last day of radiation treatment 
(IR) and after 120h of recovery (REC). Data are mean±SD (n=4, t-test, *P <0.05 vs T0)  
 
 
Fig. 28 Activation of genotoxic response after γ-rays treatment. Western blot analysis of p53 and p21 in RPE1 and 
HCT116 cells at the last day of irradiation (IR) and after 120-h of recovery (REC). Gamma-tubulin was used as a 
loading control. One representative experiment of three is shown 
 
To establish the effect of genotoxic stress on mitochondrial biogenesis, mtDNA copy number was 
first evaluated in irradiated cells. Both RPE1 and HCT116 cells showed an increase of mtDNA 
copy number both at the last day of irradiation and after 120h recovery in culture following 
irradiation, suggesting the copy number increase is an ongoing process starting with the initial 
genotoxic stimulus and proceeding beyond stimulus withdrawal. In agreement with the coupling 
between the processes of mtDNA replication and transcription (Bonawitz 2006), the latter was also 
observed to increase following irradiation, even at 120h from stimulus withdrawal (Fig. 29). 
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Fig. 29 Relative mtDNA copy number and mtRNA transcription in RPE1 (A) and HCT16 (B) cells after radiation 
treatment. Data are mean±SD (n=3, *P<0.05 vs T0). 
 
The entire mtDNA was sequenced in both cell lines after irradiation and no differences from control 
cells were found.  
In parallel to an increase of mitochondrial DNA replication and transcription, a number of 
mitochondrial proteins, nuclear encoded, showed an increased expression after γ-rays treatment in 
both cell lines. In fact, regulatory protein like TFAM and OPA1 increased from the last day of 
radiation treatment, which remained constant at 120h after stimulus withdrawal. The same trend 
was observed for VDAC1, an indicator of mitochondrial mass. Similarly, expression of 
mitochondrial respiratory complexes subunits (complex V ATP5α, complex II SDHA and SDHB 
and complex I NDUFA9, and NDUFS3 and complex III core II) displayed to increase at the last day 
of irradiation and further increase or remained unchanged at recovery (Fig. 30).  
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Fig. 30 Western blot analysis of mitochondrial proteins at T0, IR and REC in RPE1 and HCT116 cells. Gamma-tubulin 
was used as a loading control. One representative experiment of three is shown 
 
The increase of mtDNA copy number, its transcription as well as the increased expression of 
different mitochondrial proteins, regulatory, structural and of the respiratory chain, suggested an 
activation of mitochondrial biogenesis. One of its main regulators is the coactivator PGC-1β, whose 
levels have been already shown to be dependent on oncogenic stimuli such as C-MYC and HIF1α 
(Liesa 2008, Zhang 2007). Gene expression evaluation of PGC-1β after γ-rays treatment indicated a 
radiation-dependent increase in both RPE1 and HCT116 up to 2- and 3-fold respectively (Fig. 31). 
Expression of the other mitochondrial biogenesis regulator belonging to the same family of PGC-
1β, namely PGC-1α, was undetectable in both RPE1 and HCT116, consistently with the knowledge 
that it is expressed at high levels in tissues where oxidative metabolism is active, such as brown 
adipose tissue, the heart, and skeletal muscle (Puigserver 1998).  
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Fig. 31 Relative mRNA quantification of PGC-1β in RPE1(A) and HCT116 (B) cells upon irradiation. Data are 
mean±SD (n=3, *P<0.05 vs T0). 
 
These data suggested an overall increase in mitochondrial mass. This was demonstrated by loading 
cells with Mitotracker Red, a fluorescent dye that is accumulated by mitochondria of live cells as a 
function of membrane potential. After irradiation, RPE1 and HCT116 showed an increase of 
fluorescence. In parallel, calcein-AM staining, used to highlight cell morphology, demonstrated an 
increase of cell size together with the mitochondrial mass (Fig. 32). 
 
Fig. 32 RPE1 and HCT116 stained with Mitotracker Red (MTR) to evaluate mitochondrial mass and network 
morphology. Calcein-AM staining was used to highlight cells morphology. One representative experiment of 3 is 
shown. Magnification 63X/1.4. Bar: 25µM. 
 
In order to understand whether such increase in mitochondrial biogenesis was due to a 
compensatory effect following damage, the bioenergetics competence of both cell lines was 
evaluated. Following irradiation, both complex I- and II-driven ATP synthesis were shown to be 
significantly increased over twofold in RPE1 and HCT116 alike. The same result was obtained 
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upon evaluation of the activity of citrate synthase (CS), an enzymatic marker of mitochondrial mass 
(Fig. 33A). When ATP synthesis and CS activity were normalized over protein content, no changes 
were observed (Fig. 33B), suggesting that the induced mitochondrial biogenesis may not be a 
compensatory mechanism for some radiation-induced mitochondrial damage, and that cells 
remained metabolically active.  
 
 
 
 
 
Fig. 33 (A) The rate of mitochondrial ATP synthesis driven by complex I (CI) and complex II (CII) substrates, and 
cytrate sinthase activity (CS) in RPE1 and HCT116 cells after irradiation. Data are mean±SD (n=3, *P<0.05 vs T0). (B) 
ATP synthesis driven by CI and CII and CS activity normalized over protein content. 
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5.2 Role of p53 in gamma-rays induced mitochondrial biogenesis 
 
Despite the response to DNA damage may be different (quiescence, senescence, apoptosis) 
it is mediated by the ATM-p53 axis (Kruse 2009). In addition to its traditional role of guardian of 
the genome, p53 appears to regulate various aspects of mitochondrial biogenesis, in fact its physical 
interaction with mtDNA, TFAM, POLG and the coactivator PGC-1α was reported (Yoshida 2003, 
Achanta 2005, Bakhanashvili 2008). Moreover p53 may transactivate genes involved in oxidative 
metabolism, such as cytochrome oxidase deficient homolog 2 (SCO2) (Matoba 2006), or in 
glycolytic pathway, the TP53-induced glycolysis and apoptosis regulator gene (TIGAR) (Bensaad 
2006). Nevertheless, the tumor suppressor p53 has been recently called into play as a negative 
regulator of mitochondrial biogenesis through its repressor activity at the promoters of murine 
homologues of the PGC-1β family in the context of telomere dysfunction. It has been shown that 
overexpressed p53 binds its specific responsive elements on both murine PGC-1α and PGC-1β gene 
promoters to reduce expression of both regulators (Sahin 201). 
PGC-1β appeared to be the main driver of the increased mitochondrial biogenesis induced by γ-
rays, but, simultaneously, an activation of p53 was observed in both cell lines, RPE1 and HCT116. 
In order to rule out a potential role for p53 activated by DNA damage response in triggering the 
mitochondrial effect induced by γ-rays, a potential role of activator or repressor of mitochondrial 
biogenesis was examined.  
In order to verify if p53 can influence the transcription of PGC-1β, specific p53 responsive 
elements were looked in the promoter of human PGC-1β, and two close decamers were detected, 
starting at position -2732; -2706 (GRCh37 - Entrez Gene ID:133522), the first decamer differ from 
two nucleotide from the canonical sequence, the second from only one base. The two decamers are 
separate by spacer of 6 nucleotides (Fig. 34).  
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Fig. 34 (A) Schematic representation of the genomic location of the p53-responsive elements (RE) within the promoter 
region of PGC-1β. The genomic coordinates are relative to the human genome build hg19. (B) Promoter region of 
human PGC-1β, stretching from -2845 to -2542 with respect to ATG. The putative p53-RE is underlined and the two 
decamers are within the gray rectangles. 
 
 
 
To check if p53 is able to prevent the transcription of PGC-1β after radiation treatment, the 
expression of coactivator was evaluated in the syngenic HCT116 cell line knock-out for TP53, 
namely HCT116
TP53
, and in the same cells complemented with wild-type p53, HCT116
p53
. The cell 
lines HCT116
TP53
 and HCT116
p53
 were submitted to a dose of 4 Gray (Gy) every 24 hours for 4 
days. The activation of complemented p53 upon irradiation in HCT116
p53
 was confirmed by p21 
expression (Fig. 35).  
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Fig. 35 (A) Western blot analysis of p53 after HCT116
TP53KO 
complementation with wild-type p53. Gamma-tubulin was 
used as a loading control. (B) Relative expression of p21 in HCT116
p53
 (T0) e HCT116
p53
 after irradiation (IR). Data are 
mean±SD (n=3, *P<0,05 vs T0). 
 
Complementation with wild-type p53 did not prevent PGC-1β expression increase following 
irradiation, similarly to what occurred in mock HCT116 knock-out cells, in fact in both cell lines γ-
rays induced an increase of 2 fold of the level of the mitochondrial coactivator (Fig. 36).  
 
 
Fig. 36 Expression of PGC1β both in HCT116TP53KO  and in HCT116P53 upon IR. Data are mean±SD (n=3, *P<0,05 vs 
T0). 
 
Consistently, p53 did not bind to its PGC-1β weak responsive elements, both in control cells and 
after irradiation. The occupancy of p53 and histone H4 on p21 promoter were used as positive 
control of chromatin immunprecipitation experiment. Both protein significantly bound p21 
promoter after radiation treatment (Fig. 37). 
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Fig. 37 p53 and histone H4 occupancy at the promoter of PGC-1β in RPE1 cells upon IR. Data are mean±SD. The 
occupancy of p53 and H4 at the promoter of p21 in the same cells is used as positive control. (n=2, *P<0.05). 
 
In order to rule out a potential role for p53 activation in triggering the mitochondrial effects induced 
by γ-rays, mitochondrial biogenesis parameters were evaluated in a cell line knock-out for TP53 
gene,  HCT116
TP53KO
 , and in an osteosarcoma-derived cell line, HPS11, whose TP53 harbours a 
hemizygous mutation within the exon 4, i.e. the c.13055G>C. This mutation cause a replacement of 
arginine to proline in the DNA binding domain of the protein, i.e. p.156R>P (Fig. 38).  
 
Fig. 38 Electropherogram of the HPS11 cells inactivating TP53 mutation (p.156R>P) and reference sequence within the 
DNA binding domain of the protein. 
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Complementation of HCT116
TP53KO 
cells with a p.156R>P-mutated p53 confirmed that the presence 
of such mutation impairs the transcriptional activity of p53 that was unable to activate one of its 
target gene, p21, compared to HCT116
TP53KO
 complemented with wild-type p53 (Fig. 39), as 
previously observed (Youlyouz-Marfak 2008).  
 
Fig. 39 Western blot analysis of p53 and its target gene p21 in HCT116
TP53KO
, HCT116
TP53KO 
complemented with wild-
type p53 (HCT116
p53
) and with p.156R>P mutated p53 (HCT116
p53_R156P
). Gamma-tubulin was used as a loading 
control. One representative experiment of three is shown. 
 
Both HPS11 and HCT116
TP53KO
 were more sensitive to radiation treatment compared to RPE1 and 
HCT116, not surviving beyond the fourth dose of radiation, likely because of their inability to 
undergo senescence (Fig. 40). For this reason, the mitochondrial parameters were measured after 
the last doses of radiation.   
 
 
Fig. 40 Viability of (A) HPS11 and (B) HCT116
TP53
 cells at last day of radiation treatment (IR) and after 120h of 
recovery (REC). Data are mean±SD (n=4, t-test, *P <0.05 vs T0; 
#
P<0,05 vs IR). 
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Despite the absence of p53 or the mutation in the DNA binding domain, both HCT116
TP53KO
 and 
HPS11 displayed a 2.5-fold increase of mtDNA copy number after irradiation, similar to that 
occurring in TP53 wild-type cells, RPE1 and HCT116
 
(Fig. 3). MtDNA transcription increased 
concordantly with mtDNA replication, both cell lines shown an increse of 2-fold. (Fig. 41).  
 
 
 
 
 
Fig. 41 Relative mtDNA copy number and mtRNA transcription, in HPS11 and HCT116
TP53KO
 cells upon irradiation 
(IR). Data are mean±SD (n=3, *P<0.05 vs T0). 
 
 
 
The expression of both regulatory (TFAM and OPA1) and oxidative phosphorylation (NDUFA9, 
SDHA, SDHB, ATP5β, coreII) mitochondrial proteins showed to markedly increase upon 
irradiation (Fig. 42).   
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Fig. 42 Western blot analysis of mitochondrial proteins upon IR in HPS11 and HCT116
TP53KO
 cells. 
 
In TP53 wild type cells, RPE1 and HCT116, the coactivator PGC-1β appeared to be the main driver 
of the increased mitochondrial biogenesis induced by γ-rays, and, as previously demonstrated, the 
p53 protein activated by gamma-rays is not involved in the transcriptional regulation of PGC-1β. In 
HCT116
TP53
 and HPS11, PGC-1β increased respectively 2- and 4-fold after irradiation (Fig. 43).      
 
 
Fig. 43 Relative mRNA quantification of PGC-1β in HPS11 and HCT116TP53KO  after irradiation. Data are mean±SD 
(n=3, *P<0.05 vs T0). 
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The increase of mtDNA replication and transcription, the levels of expression of PGC-1β and 
mitochondrial protein after radiation treatment were concordant with mitochondrial mass increase, 
as demonstrated also by Mitotracker staining. The calcein-AM staining displayed a parallel increase 
of cell size (Fig. 44). 
 
 
 
 
 
 
Fig. 44 Mitotracker Red (MTR) and Calcein-AM staining of HPS11 (A) and HCT116
TP53KO
 (B) to evaluate 
mitochondrial mass and network morphology prior and after irradiation (IR). Magnification 63X/1.4. Bar=25µM.  
 
 
 
Altogether, these findings point to a lack of involvement of p53 in orchestrating the cell response to 
γ-rays in terms of activation of mitochondrial biogenesis.  
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5.3 Role of HIF1α stabilization in γ-rays induced mitochondrial biogenesis activation  
 
 
Solid tumors contain heterogeneous populations of cells due to in part to a limited blood 
supply that leads to lowered oxygen concentrations, acidic conditions and glucose starvation 
(Achison 2003). This hypoxic condition, a pathophysiologic characteristic of solid malignancies, 
interferes with the DNA damage induced by ionizing radiation and is therefore a major cause of 
resistance to irradiation.  
On the other hand, p53 pathway is activated by various stresses, and is one of the principal effectors 
of DNA damage response due to gamma rays (Kruse 2009).  
The mutual relationship between hypoxia and genotoxic response as well as their main effectors 
HIF1α and p53 has been subject of several studies, but the underlying mechanism remain ill defined 
(Sermeus 2011). It was reported that the loss of p53 in HCT116 cell line enhances HIF1α levels and 
augments HIF1α dependent transcriptional activation in response to hypoxia (Ravi 2000). Again, 
HIF1α dependent transcription in a panel of prostate cell lines increased from low in normal 
epithelial to high in highly metastatic cell, and this observation was related to decreasing p53 
activity in the same direction (Salnikow 2000). Vice versa, the effect of HIF1α on the stabilization 
of p53 seems to be more complicated: hypoxia has been frequently described to be a p53 inducer, 
however, in some cases, hypoxia, alone or in combination with other stresses, has no effect or even 
decreases p53 protein level (Sermeus 2011). Therefore the relationship between p53 and HIF1α is 
far from being elucidated and it has never been put within the contest of mitochondrial biogenesis 
regulation. Instead, it has been demonstrated that HIF1α acts as negative regulator of mitochondrial 
biogenesis. The transcription of PGC-1β is c-MYC dependent. HIF1α is able to inhibit c-MYC, by 
encoding a repressor or by promoting a proteasome-dependent degradation (Zhang 2007).  
It is plausible that HIF1α stabilization may repress mitochondrial biogenesis induced by radiation 
treatment and p53-dependent genotoxic could indirectly foster mitochondrial biogenesis by blunting 
the hypoxic one.  
For this purpose, HIF1α expression was analyzed during the radiation protocol. Following 
irradiation, HCT116 cells showed to have a time-dependent HIF1α decrease in terms of stabilized 
protein, which was highest at recovery (Fig. 45), and therefore antithetically followed p53 
activation and stabilization (Fig. 28).  
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Fig. 45 Western blot analysis of HIF1α in HCT116 at irradiation (IR) and after 120h of recovery (REC); gamma-tubulin 
was used as a loading control. One representative experiment of 3 is shown. 
 
 
The decrease of HIF1α observed after treatment with gamma radiation may be due to an increased 
degradation or to its decreased expression. Since HIF1α mRNA was even shown to increase at 
recovery (Fig. 46), where the relative protein product level was the lowest, it is plausible that such 
decrease was a post-transcriptional effect.  
 
 
 
Fig. 46 Relative expression of HIF1α in HCT116; data are mean±SD (n=3, *P<0.05 vs T0). 
 
The degradation of HIF1α at normal oxygen tension, is mediated by the E3-ubiquitin protein ligase 
von Hippel Lindau (VHL). The hydroxylation of two proline residues Pro
402
 and Pro
564
 by PHD2 is 
required for the binding of VHL, which leads to HIF1α ubiquitination and proteasomal degradation 
(Semenza 2009). In order to verify if VHL is involved in the degradation of HIF1α after radiation 
treatment also in presence of normal oxygen concentration, its expression was analysed at recovery, 
but any differences were observed between control and irradiated HCT116 cells (Fig. 47).  
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Fig. 47 Relative expression of VHL after irraiation in HCT116; data are mean±SD (n=3, *P<0.05 vs T0). 
 
 
Interestingly, another E3 ubiquitin protein ligase canonically involved in p53 regulation, MDM2, is 
able to promote HIF1α proteasomal degradation (Ravi 2000). To validate such a mechanism in case 
of gamma radiation treatment, the expression of MDM2 was first analysed in HCT116 after 
irradiation. MDM2 increased at IR and further increased at recovery (Fig. 48). This expression 
pattern was antithetical to HIF1α  (Fig. 45).   
 
Fig. 48 Western blot analysis of MDM2 in HCT116 after irradiation; Gamma-tubulin was used as a loading control. 
One representative experiment of 3 is shown. 
 
To demonstrate that MDM2 is involved in the degradation of HIF1α, the cell line HCT116 
transfected with plasmid expressing HIF1α wild type, HCT116HIF1α, was used.  
The degradation of HIF1α was followed after blocking protein translation with cycloeximinde (chx) 
treatment in HCT116
HIF1α
 and HCT116
HIF1α
 co-transfected with a plasmid expressing MDM2. 
HIF1α was shown to be rapidly degraded only when MDM2 was in excess within the cells.  
In HCT116
HIF1α the degradation of HIF1α began after 20 minutes of chx treatment, whereas in 
presence of MDM2 the decrease was evident already after 10 minutes of incubation with chx and 
levels diminished further after 20 minutes (Fig. 49). 
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Fig. 49 Western blot analysis of HIF1α in HCT116 over-expressing HIF1α (HCT116HIF1α) upon over-expression of 
MDM2 (+) compared to clones not over-expressing MDM2 (-). Degradation of HIF1α was evaluated by treating cells 
with 50μg/ml of cycloheximide (chx)  for 0, 10 and 20 minutes. 
 
HIF1α showed to be rapidly degraded only when MDM2 was in excess within the cells, even 
without a radiation stimulus, indicating that a basal MDM2-dependent HIF1α degradation occurs in 
HCT116. 
VHL is able to degrade HIF1α only in presence of oxygen, when the proline residues Pro402 and 
Pro
564
 are hydroxylated (Semenza 2009). The co-transfection of MDM2 in HCT116 cell line 
overexpressing a HIF1α mutated on the two residues responsible for hydroxylation by PHDs and in 
residue N803, also subject to hydroxylation in the presence of oxygen, HCT116
HIF1αTM 
, did not 
induce the degradation of HIF1α, indicating these residues to be essential. The necessity for PHDs 
to mediate MDM2-dependent degradation was further confirmed when the potent HIF1α stabilizer 
dimethyloxallylglycine (DMOG), a specific inhibitor of prolyl-hydroxylase (PHD) activity, was 
used. In such conditions, HIF1α protein did not decrease upon chx treatment (Fig. 50). 
 
 
 76 
 
 
 
Fig. 50 (A) Degradation evaluation of HIF1α mutated on the three residues responsible for hydroxylation by PHDs 
(HIF1αTM), in presence and absence of over-expressed MDM2. Degradation of HIF1α was evaluated by treating cells 
with 50μg/ml of cycloheximide (chx) for 0, 10 and 20 minutes. (B) Degradation evaluation of HIF1α in presence and 
absence of over-expressed MDM2, upon forced pharmacological HIF1α stabilization by 1µM DMOG. Degradation of 
HIF1α was evaluated by treating cells with 50μg/ml of cycloheximide (chx)  for 0, 10 and 20 minutes. 
 
 
 
 
MDM2 is a transcriptional target of p53 (Manfredi 2010), but mitochondrial biogenesis activation 
occurs also in absence of functional tumor suppressor. The decreased expression after irradiation of 
HIF1α was observed also in HPS11 (Fig. 51). Like in cell line wild type for TP53, HCT116, the 
genotoxic stress induced an increase of MDM2. 
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Fig. 51 Western blot analysis of HIF1α and MDM2 in HPS11 after irradiation; Gamma-tubulin was used as a loading 
control. One representative experiment of 3 is shown. 
 
 
 
The genotoxic response and hypoxia are closely interrelated. Under normal oxygen tension, when 
HIF1α can be degraded by the ubiquitin-proteasome system, the genotoxic response activated by 
gamma rays treatment prevails the hypoxic (Semenza 2009). 
Subsequentely, hypoxic response was forced concomitantly to genotoxic one, with the aim to reveal 
if mitochondrial biogenesis would be activated according to the prevalence of one or the other 
response. 
The specific inhibitor of PHD activity, dimethyloxallyl-glycine (DMOG), was used to stabilize 
HIF1α. DMOG was added to the culture medium the day before the first dose of radiation and was 
maintained for the entire duration of  irradiation. HCT116 cells shown to respond well in terms of 
toxicity, in fact survived and remained able to proliferate despite the combined treatment. DMOG-
treated cells presented HIF1α stabilized for the entire duration of the radiation treatment and 
increased expression of canonical HIF1α-responsive genes lactate dehydrogenase A (LDHA) and 
BCL2/adenovirus E1B 19 KDa interacting protein 3-like (BNIP3L) (Fig. 52). 
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Fig. 52 (A) Viability of HCT116 irradiated and treated with 1µM DMOG, Data are mean±SD (n=4, t-test, *P <0.05 vs 
T0; 
#
P<0,05 vs IR). (B) Western blot analysis of HIF1α  in HCT116 irradiated and treated with 1µM DMOG, Gamma-
tubulin was used as a loading control. One representative experiment of 3 is shown. (C) Relative expression of BNIP3L 
and LDHA in RPE1 cells before and after treatment with 1µM DMOG and irradiation. Data are mean±SD (n=3, t-
test,*P<0.05).  
 
 
 
HCT116 with HIF1α stabilized did not display increase in mtDNA copy number  irradiation. The 
same finding was obtained when cells were treated with another HIF1α stabilizer, the iron chelator 
desferrioxamine (DFO) (Fig. 53).  
 
Fig. 53 Relative mtDNA copy number HCT116 cells with stabilized HIF1α after 1µM DMOG treatment (A) or 250nM 
DFO (B) and irradiated. Data are mean±SD (n=3, *P<0.05 vs T0). 
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Concordantly with mtDNA copy number and with a repressive effect of HIF1α on mitochondrial 
biogenesis already demonstrated (Zhang 2009), PGC-1β expression after irradiation was not 
increased in DMOG-treated cells (Fig. 54).  
 
 
 
Fig. 54 PGC1β expression after irradiation in HCT116 cells with stabilized HIF1α after 1µM DMOG treatment. Data 
are mean±SD (n=3, *P<0.05 vs T0). 
 
 
 
Accordingly, neither mtDNA maintenance proteins (OPA1 and TFAM), nor respiratory complexes 
subunits (SDHA, SDHB, coreII, NDUFA9 and ATP5β) were shown to increase after irradiation in 
DMOG-treated cells displaying a chronically stabilized HIF1α (Fig. 55). 
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Fig. 55 Western blot analysis of mitochondrial proteins in HCT116 treated with DMOG and irradiated. γ-tubulin was 
used as a loading control. One representative experiment of 3 is shown. 
 
Overall, no increase of mitochondrial mass was observed, as evaluated by Mitotracker staining, 
despite a net cell mass increase as observed in all other cell lines irradiated, as evidenced by 
calcein-AM staining (Fig. 56).  
 
 
Fig. 56 Staining with Mitotracker Red (MTR) and Calcein-AM to evaluate mitochondrial mass and network 
morphology in HCT116 treated with DMOG and irradiated . Magnification 63X/1.4. Bar=25µM. 
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Analogous findings were obtained when the cell line RPE1 was treated with DMOG and irradiated. 
Also in these cells, the stabilization of HIF1α prevented the activation of the mitochondrial 
biogenesis induced by radiation, in fact, when the cells were treated with DMOG there was no 
difference between control and irradiated, both in terms of mitochondrial DNA copy number and 
PGC-1β expression (Fig. 57). 
 
 
 
 
 
Fig. 57 (A) Relative mtDNA copy number. Data are  mean±SD (n=3, t-test, *P<0.05) and (B) relative PGC-1β 
expression  after γ-rays treatment in RPE1 with HIF1α stabilized by DMOG treatment. Data are mean±SD (n=3, t-test, 
*P<0.05). 
 
 
Concordantly, mitochondrial protein like TFAM and some subunits of the respiratory chain did not 
increase after irradiation in RPE1 treated with DMOG (Fig. 58).  
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Fig. 58 Western blot analysis of mitochondrial proteins in RPE1 with HIF1α stabilized by DMOG treatment. One 
representative experiment of 3 is shown.  
 
Mitochondrial DNA copy number, the main parameter used to evaluate mitochondrial biogenesis, 
was also measured in HCT116
TP53KO 
 irradiated and treated with DMOG. Like in others cells, the 
stabilization of HIF1α prevented the activation of gamma rays-induced mitochondrial biogenesis 
(Fig. 59).  
 
Fig. 59 Relative mtDNA copy number after γ-rays treatment in HCT116TP53KO cells with HIF1α stabilized by 1µM 
DMOG. Data are mean±SD (n=3, t-test, *P<0.05). 
 
Overall, these data indicate that the hypoxic response prevails over the genotoxic one in terms of 
mitochondrial biogenesis activation that may be induced by irradiation via an indirect mechanism, 
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namely a re-positioning of MDM2 from p53 to HIF1α. This would foster hydroxylated HIF1α 
degradation upon p53 activation, preventing HIF1α to inhibit mitochondrial biogenesis.    
 
 
 
 
5.4 Role of HIF1α in gamma rays-induced cellular senescence 
 
 
Cellular senescence has emerged as a programmed cellular stress response that is induced 
due to the accumulation of damage. The activation of senescence induced by DNA damage leads to 
an irreversible arrest phenotype that is characterized by the activation of p53 or RB proteins. In this 
way, senescence can be seen as a tumor suppressor mechanism that prevents excessive cellular 
division, or division of damaged cells, and its induction may represents the goal of anticancer 
radiotherapy (Nardella 2011).  
After irradiation, both RPE1 and HCT116 acquired the typical features that characterized senescent 
cell: increase in size, flattened and shaped morphology (Rodier 2011). The marker that is commonly 
used to assess the activation of senescence process is a cytochemical assay aimed at evaluating the 
activity of the lyssosomal enzyme β-galactosidase (SA-βGal). Senescence cells are characterized by 
an increased activity of this enzyme whose contribution to senescence has not been elucidated 
(Debacq-Chainiaux 2009). The positivity of the irradiated RPE1 and HCT116 cells to the β-
galactosidase assay together with morphological changes showed that the genotoxic stress induced 
the activation of cellular senescence (Fig. 60).  
 
 
Fig. 60 Senescence-associated β-galactosidase staining in RPE1 and HCT116 irradiated. One representative experiment 
of 3 is shown. Magnification 10X 
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The pathways p53-p21 and pRB-p16
INK4A 
are the two effectors of senescence that determine the 
block of cell proliferation and morphological changes typical of senescent cells. It has been shown 
that these two pathways may interact or act indipendently in regulating senescence (Nardella 2011). 
The activation of genotoxic response in HCT116 and RPE1 cell was characterized by a stabilization 
of p53 and consequently by the increase of its target p21. To determine if also the pathway of pRB–
p16 was involved in regulating the activation of senescence in these cell lines, the expression of p16 
was evaluated (Fig. 61). Since this protein decreased after irradiation, the pathway pRB-p16 was 
not involved in activation of senescence response that it was regulated by p53 and p21.  
 
Fig. 61 Western blot analysis of p16 in RPE1 and HCT116 cell  irradiated. Gamma-tubulin was used as a loading 
control. One representative experiment of 3 is shown. 
 
In an opposite manner to p53, HIF1α enhances proliferation and survival of tumors cells, and has a 
profound effect on the response to radiotherapy (Harada 2011).  
Previously, it has been demonstrated that mitochondrial biogenesis is activated parallel to the 
genotoxic response, which in the presence of p53, determines the increased expression of the 
inhibitor of cyclin-kinase p21. HIF1α acts contrary, represses the expression of PGC-1β and then 
blocks the activation of mitochondrial biogenesis induced by ionizing radiation. 
Interestingly, p53 stabilization did not increase after irradiation in DMOG-treated RPE1 and 
HCT116 cells, in the same fashion as its main target p21 and its regulator MDM2, whereas p16 was 
not shown to change (Fig. 62). 
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Fig. 62 Western blot analysis of p53, p21, MDM2 and p16 in RPE1 and HCT116 cells treated with DMOG and 
irradiated. γ-tubulin was used as a loading control. 
 
The genotoxic stimulus was not able to activate p53 in presence of stabilized HIF1α, as no binding 
of p53 could be detected on the p21 promoter in DMOG-RPE1 cells, and consequently no 
acetylation occurred, evaluated by the occupancy of histone H4 in the same regions of the promoter 
analyzed for the presence of p53 (Fig. 63) 
 
 
Fig. 63 P53 and histone H4 occupancy at the promoter of p21 in irradiated RPE1 cells, in presence or absence of 
stabilized HIF1α by 1µM DMOG. Data are mean±SD (n=2, *P<0.05 vs T0). 
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Accordingly with the protein expression level of p21 and MDM2, other two target genes of p53: 
BAX and GADD45A were not increased in RPE1 after irradiation (Fig. 64).  
 
 
 
Fig. 64 Relative expression of p53-responsive genes BAX and GADD45A in RPE1 cells, in presence or absence of 
stabilized HIF1α by 1µM DMOG, and irradiated. Data are mean±SD (n=3, *P<0.05 vs T0). 
 
In both cell lines, RPE1 and HCT116, the non-stabilization of p53, and consequently of p21, would 
indicate that HIF1α is able to block the process of senescence, induced by gamma radiation. 
β-galactosidase assay confirmed that HIF1α stabilization by DMOG was able to prevent cells to 
undergo senescence, as DMOG-treated cells did not show a different staining compared to controls 
after irradiation (Fig. 65).  
 
 
Fig. 65 Senescence-associated β-galactosidase staining in RPE1 and HCT116 irradiated and treated with DMOG. One 
representative experiment of 3 is shown. Magnification 10X. 
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The same effect was observed when DFO was used (Fig. 66).  
 
 
 
 
 
Fig. 66 β-gal staining of RPE1 and HCT116 cells irradiated and treated with 250nM DFO. One representative 
experiment of 3 is shown.
 
Magnification: 10X. 
 
 
 
Taken together, these data suggest that, along with mitochondrial biogenesis, HIF1α stabilization 
was able to blunt the cell senescent response, suggesting the two processes to be concomitant.  
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5.5 Evaluating the mtDNA copy number as a predictive marker of HIF1α stabilization after 
radiotherapy in vivo 
 
Hypoxia is known to induce tumor radioresistance through the activation of HIF1α. Consistent with 
these findings, there is clinical evidence that  the size of the intratumoral hypoxic fraction and the 
level of HIF1α correlate with a poor prognosis after radiation therapy (Harada 2011). Inhibition of 
HIF1α activity could therefore represent an important component of anti-tumoral therapies 
(Semenza 2003). Strategies to quantify and image hypoxia in clinical tumors have received 
considerable attention because of the significant impact of hypoxia/HIF1α activity on the effect of 
radiation therapy (Harada 2011).  
In the previous experiments, it was shown how mitochondrial biogenesis is regulated by 
stabilization of HIF1α. A collection of healthy tissue rectal biopsies taken from subject who had 
undergone radiation treatment for prostate cancer was evaluated, since γ-rays also hit the rectum 
lining. MtDNA copy number was measure in rectal epithelium before irradiation compared to 
biopsies taken two months after the end of therapy.  
32 subjects were analyzed and mtDNA copy number was shown to be significantly higher in 16/32 
(59%) subjects and decreased in only two sample (Fig. 67). 
 
Fig. 67 Absolute mtDNA copy number in rectal biopsies of patients subjected to radiotherapy for prostate carcinoma, 
prior (pre-IR) and post-irradiation (post-IR). Data are mean±SEM (*P<0.05; paired t-test).  
 
Considering all data together, the mtDNA copy number was significantly increased in all subjects 
analyzed (pre-IR vs post-IR, P<0.05), suggesting the radiation trigger had lasted long after the 
withdrawal of the stimulus (Fig. 68). 
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Fig.68 Median comparison of all pre- and post-irradiation biopsies (Wilcoxon Rank test, *P<0.05 vs Pre-IR).   
 
 
The expression of HIF1α was evaluated in all tissues pre e post irradiation. A tight correlation was 
found between HIF1α stabilization and mtDNA copy number. In 8/10 cases in which the number of 
copies is the same or decrease, HIF1α increase after irradiation, vice versa in 9/12 cases in which 
mtDNA increase after γ-rays treatment, HIF1α does not change or decrease (Fig. 69).  
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Fig. 69 (A) Western blot analysis of the expression of HIF1α in representative cases in which the mtDNA copy number 
was found not to change or decreased after radiation treatment. (B) Western blot analysis of the expression of HIF1α in 
representative cases in which mtDNA copy number increased after radiation treatment. Beta-actin (ACT) was used as a 
loading control. One representative blot of 3 is shown. 
 
 
 
These data confirm the negative relationship between HIF1α and mitochondrial biogenesis and 
suggest a HIF1α regulated control of the  γ-rays induced biogenesis.  
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6. DISCUSSION 
 
This study demonstrates that γ-rays, in doses corresponding to those commonly used during anti-
cancer therapy, potently induce a net mitochondrial biogenesis. Such induction is p53-independent 
and is blunted by HIF1α stabilization, which occurs during the hypoxia response.  
 
Recent transcriptomic, proteomic, functional and structural studies of mitochondria of cancer cells 
indicate that an impaired biogenesis and activity of the organelle is required for the development of 
some tumors (Formentini 2010). The decrease of mitochondrial activity in cancer cells may have 
multiple reasons, related either to the input of reducing equivalents to the electron transfer chain or 
to direct alterations of the mitochondrial respiratory complexes (Gasparre 2013). Interestingly 
certain tumor subtypes, identified as oncocytic, are characterized by abnormal biogenesis of non-
functional mitochondria in their cells. These tumors are in most cases benign, having a low 
proliferative potential, and are not aggressive (Gasparre 2010).  
A particular type of relapses after γ-rays was observed in patients with colorectal cancer, where 
oncocytic features were acquired in the recurring neoplasia after radiation therapy (Rouzbahman 
2006, Ambrosini-Spaltro 2006) suggesting a potential connection between mitochondrial biogenesis 
and radiation treatment. An increase in mitochondrial mass and function had been previously 
observed in lung carcinoma cells after exposure to X-rays (Malakhova 2005). In the present thesis 
work it was demonstrated that also γ-rays are able to induced an increase of mitochondrial mass and 
a thorough characterization of mitochondrial changes that occur when a genotoxic stimulus is 
administered to cells was performed. In different cell line after irradiation, an increase of one of the 
master regulators of mitochondrial biogenesis, PGC-1β was observed. In parallel, mitochondrial 
DNA replication, transcription as well as mitochondrial protein expression and mass were observed 
to increase. Simultaneously, one of the main effectors of the genotoxic response, p53, was 
stabilized. To date, a clear link between this phenotype and the canonical cellular responses to DNA 
damage has not been elucidated. The increased mitochondrial mass and function in irradiated cells 
was observed simultaneously to stabilization of p53 and increased expression of its target gene p21, 
positive staining for SA-β-Gal and enlarged cell size, that are all hallmark of cell senescence 
(Rodier 2011). Mitochondria are semi-autonomous organelles. Nuclear-encoded proteins are needed 
for their biogenesis, such as the DNA polymerase gamma or the fusion protein OPA1, yet 
checkpoints for mtDNA replication, for instance, do not seem to exist or are hypothesized to be 
different from those of nuclear DNA (Singh 2006). Moreover, the mitochondrial network fission 
and fusion are believed to be independent from cell division. Overall, mitochondria continue to 
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proliferate despite lack of cell division, in the senescent yet metabolically active G1 arrested cells. 
The mitochondrial biogenesis increase observed after γ-rays treatment, therefore, may not be an 
actively induced process, and it is surely not a compensatory effect since we showed mitochondrial 
function to be augmented in irradiated cells. This thesis results suggest a relation between 
mitochondrial biogenesis and cellular senescence. The increase of mitochondrial function may be 
an obligated condition for the activation of senescence, maintaining these cells metabolically active, 
and it is also possible that these processes are activated simultaneously by the same factor. It is well 
established that p53, the main effector of genotoxic response, regulates various aspect of 
mitochondrial biogenesis, but its role seems debatable. The physical interaction of tumor suppressor 
with mtDNA, TFAM, POLG and the coactivator PGC-1α was reported (Yoshida 2003, Achanta 
2005, Bakhanashvili 2008). Overall, these data suggest a positive control of p53 on mitochondrial 
biogensis. Nevertheless, p53 has been recently called into play as negative regulator through its 
repressor activity at the promoters of murine homologues of the PGC-1β family in the context of 
telomere dysfunction (Sahin 2011). After γ-rays treatment, an increased expression of coactivator 
PGC-1β was observed in HCT116TP53KO such as in same cells complemented with wild-type p53. 
Furthermore p53 did not bind PGC-1β promoter in irradiated RPE1. Overall these data suggest that 
in human p53 does not act as negative regulator of mitochondrial biogenesis in the context of 
gamma rays treatment.  
Although the presence of p53 is an obligatory condition for the activation of cell senescence 
induced by γ-rays, the tumor suppressor is not necessary for the increase of mitochondria in 
irradiated cells, in fact a net biogenesis like in RPE1 and HCT116 was observed also in cells knock-
out for TP53 and in osteosarcoma cell line (HPS11) whose TP53 harbours a mutation in 
hemizygosity within the DNA binding domain that impair its transcriptional activity. 
Interestingly, the effect of genotoxic stress in these cell lines was more detrimental, both HPS11 
and HCT116
TP53KO
 did not survive beyond the fourth dose of radiation, likely because of their 
inability to undergo senescence, in fact the absence of functional p53 pathway prevent the 
transcriptional activation of p21. Therefore, mitochondrial biogenesis activation was observed in 
two different positive conditions in term of inhibition of tumor proliferation: senescence and cell 
death. Further experiments are necessary to identify whether the apoptotic pathway is activated in 
these cell.  
These data also demonstrate that mitochondrial biogenesis and cellular senescence are not strictly 
correlated, but these two process may be possibly activated by a common effector, upstream to p53 
in the DNA damage cascade response. It should be also interesting to evaluate whether a cell unable 
to trigger mitochondrial biogenesis after γ-rays treatment can activate cellular senescence. 
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Nonetheless, the influence of p53 over mitochondrial biogenesis may be indirect, via the previously 
demonstrated MDM2-mediated degradation of HIF1α, the main effector of hypoxic response. 
MDM2 expression increased after irradiation, parallel to a time-dependent degradation of HIF1α.  
Generally, MDM2 is involved in the negative regulation of the tumor suppressor p53. This occurs 
through two main mechanisms. First, the direct binding of MDM2 to the N-terminal and of p53 
inhibits the transcriptional activation function of p53, second, MDM2 possesses E3 ubiquitin ligase 
activity that targets p53 for modification and subsequent degradation through the 26S proteasome. 
Although its role as an oncogene via suppression of p53 function remains clear, growing evidence 
argues for p53-independent effects, as well as the remarkable possibility that MDM2 has tumor 
suppressor functions in the appropriate context (Manfredi 2010). In this study one of these 
situations was demonstrated: in fact MDM2 was able to degrade HIF1α, like observed in previous 
work (Ravi 2000).  
It was observed that MDM2 expression increased after irradiation, parallel to stabilization ofp53. It 
is therefore plausible to suppose that when p53 is activated and phosphorylated upon a genotoxic 
stimulus, such as γ-rays, MDM2 may not preside to its degradation and be re-directed towards 
HIF1α, whose degradation would hence be fostered. This hypothesis is further justified by the 
increase in MDM2 protein observed also in HCT116 cells devoid of p53 and in HPS11, indicating 
that post-radiation MDM2 increase may also occur independently of p53 stabilization (Manfredi 
2010), either through other members of the p53 family, such as p73 (Davis 2001) or through an 
NFκB-mediated induction (Busuttil 2010), and contribute to HIF1α degradation and mitochondrial 
biogenesis increase we observed in p53 knock out cells as well. It is well known that both HIF1α 
and the mitochondrial respiratory chain are considered the two fundamental oxygen sensors of the 
cell. As O2 tension decreases, in fact, HIF1α stops becoming hydroxylated on essential proline 
residues and is hence stabilized. It may then act as a heterodimeric transcription factor to transcribe 
within the nucleus a large set of genes involved in the regulation of glycolysis and neoangiogenesis 
(Koh 2012, Semenza 2011). Since O2 is also the major substrate for the electrons of the respiratory 
chain, the latter is shut off during hypoxia, and cells must rely on non-oxidative metabolism for 
ATP production. At normal oxygen condition, increased expression of MDM2 is sufficient to 
degrade HIFα, as previously demonstrated (Ravi 2000). This study demonstrates that the 
mechanisms are likely analogous to the O2-dependent hydroxylation by PHDs, since a mutant 
HIF1α did not respond to MDM2 degradation. Similar results were obtained when cells were 
treated with an inhibitor of PHDs.  
Under normoxia, HIF1α is rapidly degraded, whereas hypoxia leads to stabilization and 
accumulation of HIF1α. However, under certain normoxic conditions, typical of cancer cells, HIF1α 
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expression can be increased; for example, mutations in the von Hippel- Lindau protein stabilize 
HIF1α protein and PI3K/AKT/mTOR activity stimulates translation of HIF1α mRNA (Gillies 2008, 
Sun 2007). In this context the relation between genotoxic and hypoxic response may be different. 
When hypoxia was induced in parallel to a genotoxic stimulus, the former response prevailed over 
the latter. In fact, cells treated with HIF1α specific stabilizer DMOG were prevented to undergo cell 
senescence when irradiated, as indicated by the unequivocal β-galactosidase marker and by the lack 
of p21 increase. Interestingly, p53 stabilization also appeared to be prevented, consequently there 
was no increase of its target genes, among which MDM2. In this condition, the absence of MDM2 
the hypoxic response prevail over the genotoxic one, and after radiation treatment cells remained 
still able to replicate. Nonetheless, further investigation is warranted to understand in detail why the 
p53-p21 axis appears to be repressed upon HIF1α stabilization.  
In terms of mitochondria, it is most interesting that the γ-rays-induced biogenesis is also strongly 
blunted, in parallel to senescence, during hypoxia. HIFα stabilization blocked the expression of 
PGC-1β, and consequently the increase of mitochondrial mass.  
These findings therefore point to an indirect control of mitochondrial biogenesis by p53, whose role 
would be to allow, upon stabilization, MDM2 to be re-directed to HIF1α, with a subsequent release 
of the basal inhibition by the latter over PGC-1β, which appears to be the only master regulator of 
the PGC family involved in γ-rays induced biogenesis. These data also shed light on the 
controversial role of MDM2 in orchestrating the balance between genotoxic and hypoxic response 
(Sermeus 2011, Chen 2003). Although it has been suggested that MDM2 may either degrade or 
stabilize HIF1α, the results point to the former hypothesis as the most likely, at least upon γ-rays 
treatment (Fig. 70).  
 
 95 
 
 
 
Fig. 70 In normal condition, MDM2 maintains low the expression of p53 (1), upon gamma radiation stimulus (2), the 
cell triggers the genotoxic response through P53 activation, this impaired the ability of MDM2 to interact with p53 and 
can be re-directed to HIF1α  (5) and turns to proteosomal degradation of HIF1α, for which the P402, P564 and N803 
HIF1α residues are necessary. The HIF1α directed repression of PGC1β is therefore inhibited (6), which enables 
activation of mitochondrial biogenesis (7). The stabilization of p53 leads to activation of its target gene, MDM2 (3), that 
occurs also in absence of p53 (4) and p21. The last protein is necessary for the activation of senescence pathway (8).  
 
 
 
The opposing relation between HIF1α stabilization and mitochondrial biogenesis activation was 
also demonstrated in vivo. Rectal tissues from individuals who underwent radiotherapy for prostate 
cancer were shown to retain a ‘scar’ of activated mitochondrial biogenesis two months after the 
withdrawal of the γ-rays stimulus. This occurred only when local hypoxia had not set in, as shown 
by the decreased HIF1α expression.  
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A significance of the increase of mitochondrial mass after irradiation should be deducted by 
analyses of oncocytic tumors. The irradiated cells presented a typical oncocytic phenotype: 
abnormal accumulation of mitochondria, low proliferation and destabilization of HIF1α. The vast 
majority of oncocytomas are characterized by accumulation of non-functional mitochondria, due to 
the presence of disruptive mtDNA mutation. To date, there are no data relative to the presence of 
mutations in mitochondria that accumulate in tissues of patient that undergo radiotherapy and 
acquired an oncocytic phenotype (Rouzbahman 2006, Ambrosini-Spaltro 2006). After irradiation, 
cells analysed did not present mutations on the mitochondrial genome, but, interestingly, 
oncocytomas may develop also in absence of mtDNA mutation. A parotid oncocytoma were 
described in patients with FLCN mutation, causing the autosomal dominant syndromes Birt–Hogg–
Dubè, (Pradella 2013), suggesting that there could be an alternative determinant to pathogenic 
mtDNA mutation in oncotic phenotype in cancer cells. Oncocytoma are consider a benign lesion, in 
fact these tumors are characterized by a low-grade of proliferation. This “senescent-like” phenotype 
is due to a chronic destabilization of HIF1α, that explains the low aggressive tumor behaviour. It is 
therefore plausible to interfere regards the benign nature of oncocytic phenotypes occurs after 
radiation treatment. On the other hand, this thesis work provides an explanation for the reason why 
HIF1α is an obligatory condition in oncocytic cell: first of all the activation of hypoxic response 
impair the increase of mitochondrial biogenesis and through its repressive role on genotoxic 
response blunts the cell-cycle inhibitor p21, as a consequence tumor cells maintain the capacity to 
proliferate. 
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7. CONCLUSION 
 
Today, almost 100 years since the first clinical observation of the importance of hypoxia for 
radiotherapy, the role of hypoxia has been intensively explored with regard to both its influence on 
cancer progression and resistance to therapy. Different studies demonstrate that hypoxia is 
associated with poor prognosis after radiotherapy. For this reason, numerous clinical trials have 
explored the various means of modifying hypoxia and have demonstrate a significant survival 
benefit and no difference in the risk of developing distant metastases (Overgaard 2007). Therefore, 
it is important to develop imaging strategies for both hypoxia and HIF1α activity (Harada 2011). 
The principles for measuring hypoxia in human tumors are mainly based on three different 
methods. The first includes measurement of the physical amount of oxygen in a tissue. The second 
is the use of hypoxic markers that are reduced under the presence of hypoxia and can subsequently 
be identified by various imaging methods such as immunohistochemistry or positron emission 
tomography. The third principle is more indirect because it is an identification of biologic 
processes, gene expression that are known to be caused by the presence of hypoxia. Most of this is 
associated with the hypoxia inducible factor-1 alpha cascade (hypoxia inducible factor-1 alpha and 
carbonic anhydrase IX) or other processes involved in hypoxia (Overgaard 2007).  
In this study was demonstrate that mitochondrial biogenesis parameters like mitochondrial DNA 
copy number could be used for the prediction of hypoxic status of tissue after radiation treatment. γ-
rays induce an increase of mitochondrial mass and function, in response to a genotoxic stress that 
pushes cells into senescence. Mitochondrial biogenesis is only indirectly regulated by p53, whose 
activation triggers a MDM2-mediated HIF1α degradation, leading to the release of PGC-1β 
inhibition by HIF1α. On the other hand, this protein blunts the mitochondrial response to γ-rays as 
well as the induction of p21-mediated cell senescence, indicating prevalence of the hypoxic over the 
genotoxic response. Finally in vivo, post-radiotherapy mtDNA copy number increase well correlates 
with lack of HIF1α increase in the tissue, concluding this may be a useful molecular tool to infer the 
trigger of a hypoxic response during radiotherapy, which may lead to failure of activation of cell 
senescence. 
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9. APPENDIX A 
 
Primer TP53 sequencing 
 
 PRIMER FW PRIMER RV 
Exon 2/3 5’-ATCCCCACTTTTCCTCTTGC-3’ 5’-AGCCCAACCCTTGTCCTAC-3’ 
Exon 4 5’-CCTGGTCCTCTCTGACTGCTCT-3’ 5’-CAGGCATTGAAGTCTCATGG-3’ 
Exon 5 5’-CTGTCTCCTTCCTCTTCCTACAG-3’ 5’-AACCAGCCCTGTCGTCTCT-3’ 
Exon 6 5’-CAGGCCTCTGATTCCTCACT-3‘ 5’-CTTAACCCCTCCTCCCAGAC-3’ 
Exon 7 5’-CTCATCTTGGGCCTGTGT-3’ 5’-TGGAAGAAATCGGTAAGAGGTG-3’ 
Exon 8 5’-GGGACAGGTAGGACCTGATTT-3’ 5’-ATAACTGCACCCTTGGTCTCC-3’ 
Exon 9 5’-GGGACAGGTAGGACCTGATTT-3’ 5’-TCAGGCAAAGTCATAGAACCA-3’ 
Exon 10 5’-AACTTGAACCATCTTTTAACTCAGC-3’ 5’-GGAATCCTATGGCTTTCCAAC-3’ 
Exon 11 5’-GTCATCTCTCCTCCCTGCTTC-3 5’-CACAACAAAACACCAGTGCAG-3’ 
 
Primer Real-time PCR 
 PRIMER FW PRIMER RV 
PGC-1β 5’-AGTCAACGGCCTTGTGTTAAGAG-3’ 5’-ACAACTTCGGCTCTGAGACTG-3’ 
HIF1α 5’-TTTTTCAAGCAGTAGGAATTGGGA-3’ 5’-GTAATGTAGTAGCTGCATGATC-3’ 
P21 5’-CCGAAGTCAGTTCCTTGTGG -3’ 5’-CATGGGTTCTGACGGACAT -3’ 
BAX 5’-AGCAAACTGGTGCTCAAGG-3‘ 5’-TCTTGGATCCAGCCCAAC-3’ 
GADD45A 5’-GAGAGCAGAAGACCGAAAGG-3’ 5’-TGACTCAGGGCTTTGCTGA-3’ 
MT-ND5 5’-ATCCTTCTTGCTCATCAGTTG-3’ 5’-GGCTATTTGTTGTGGGTCTC-3’ 
 
Primer Chromatin Immunoprecipitation 
 PRIMER FW PRIMER RV 
PGC-1β_REp53 5’-CACTCCCAAGTTTGGCCTC -3’ 5’-AGCACTAAGGACTTGAATTCTC-3’ 
P21_RE_p53 5’-GTGGCTCTGATTGGCTTTCTG -3’ 5’-CTGAAAACAGGCAGCCCAAG -3’ 
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